# Medical Question & Answer

**Sample ID**: f2518cfa-63dd-5251-f5de-5e04f694e6e3
**Dataset Index**: 303036

---

## Question

What is the ICD-10-CM code for a benign carcinoid tumor when the primary site is unspecified?

---

## Answer

> Let's see… What do we have here? The user is asking for the ICD-10-CM code for a benign carcinoid tumor when the primary site is unspecified. Let's break this down step-by-step. First, I need to think about the ICD-10-CM coding framework for neuroendocrine neoplasms and whether "benign" versus "malignant" behavior is captured. Then, I should verify whether there is a specific code for "benign carcinoid, unspecified site" or if an unspecified neuroendocrine tumor code must be used. Next, I will check for any laterality or seventh-character requirements that could complicate coding. Finally, I will confirm the most appropriate code and ensure it aligns with ICD-10-CM conventions and payer guidance on unspecified codes.

> Let me first confirm the coding framework. In ICD-10-CM, neuroendocrine tumors are generally classified under the D3A category for benign neuroendocrine tumors, with subcategories by site, and the behavior (benign versus malignant) is embedded in the code itself rather than added as a separate digit, which differs from ICD-O-3 where behavior is a separate code [^notfound].

> Wait, let me verify whether a "benign carcinoid, unspecified site" code exists. I initially thought there might be a direct match like D3A.00, but hold on, I should verify the ICD-10-CM tabular list. On review, there is no code that literally reads "benign carcinoid tumor, unspecified site"; instead, the closest fit is D3A.00 for benign carcinoid tumor of unspecified site, which functionally captures the clinical scenario even though the label does not repeat "benign" in the descriptor, because the D3A category already denotes benign neuroendocrine tumors [^notfound].

> I should confirm the exact code and its construction. The correct ICD-10-CM code is D3A.00, where D3A is the category for benign neuroendocrine tumors, the decimal separates category from subcategory, and .00 indicates unspecified site; there is no additional seventh character required for this code, so no placeholder X is needed, which simplifies documentation in this case [^notfound].

> Hold on, let's not jump to conclusions about unspecified codes being unacceptable. I need to check payer guidance. ICD-10-CM allows unspecified codes when clinical information is insufficient, and payers are generally instructed not to deny claims solely for lack of specificity; therefore, using D3A.00 is appropriate when the primary site truly cannot be determined at the time of coding, with the expectation that clinicians will document the site when it becomes known [^d495525c].

> Let me consider alternatives in case the behavior is uncertain rather than clearly benign. If the behavior is uncertain or borderline, the code would shift to the D37–D48 range for neoplasms of uncertain behavior, but the user explicitly asked for a benign carcinoid; so, assuming confirmed benign histology, D3A.00 remains the correct choice, whereas uncertain behavior would be coded differently and should be avoided here unless clinically justified [^notfound].

> Final answer: The ICD-10-CM code for a benign carcinoid tumor with unspecified primary site is D3A.00 [^notfound].

---

The ICD-10-CM code for a benign carcinoid tumor with an unspecified primary site is **D3A.00**. This code specifically denotes a **benign carcinoid tumor** when the anatomical location is not documented. If the primary site becomes known, use the site-specific benign carcinoid code (e.g. D3A.01 for small intestine, D3A.02 for appendix, D3A.03 for large intestine, D3A.04 for bronchus and lung). Accurate coding supports appropriate clinical tracking and billing, and clinicians should document the primary site whenever possible to enable more specific coding [^d495525c].

---

## ICD-10-CM code for benign carcinoid tumor, unspecified site

The ICD-10-CM code for a benign carcinoid tumor with an unspecified primary site is **D3A.00**. This code is part of the D3A category, which encompasses benign neuroendocrine tumors, including carcinoid tumors. The ".00" suffix indicates that the specific anatomical site of the tumor is not documented.

---

## Clinical significance of benign carcinoid tumors

Benign carcinoid tumors are **neuroendocrine tumors** that arise from enterochromaffin cells and can occur throughout the gastrointestinal tract, lungs, and other organs. They are generally slow-growing and indolent but have the potential to metastasize, particularly to the liver and lymph nodes. The clinical behavior and prognosis of carcinoid tumors vary significantly depending on their primary site, size, and histological features [^94b3fb48].

---

## Importance of specifying the primary site

While the D3A.00 code is appropriate when the primary site is unspecified, it is clinically important to document the **specific anatomical location** of the tumor whenever possible. Specifying the primary site enables more accurate coding, better clinical management, and improved epidemiological tracking. Common primary sites for carcinoid tumors include:

- Small intestine (D3A.01)
- Appendix (D3A.02)
- Large intestine (D3A.03)
- Bronchus and lung (D3A.04)

---

## Clinical documentation and coding best practices

To ensure accurate coding and optimal patient care, clinicians should adhere to the following best practices:

- **Document the specific anatomical site**: Whenever possible, document the exact location of the carcinoid tumor (e.g. small intestine, appendix, large intestine, bronchus, lung).
- **Use unspecified codes judiciously**: Reserve the D3A.00 code for cases where the primary site genuinely cannot be determined or documented.
- **Update documentation**: If additional information becomes available regarding the primary site, update the medical record and coding accordingly.

---

## Impact of unspecified coding on clinical care and billing

Using unspecified codes such as D3A.00 can have several implications:

- **Limited clinical specificity**: Unspecified codes may limit the ability to track disease patterns, conduct research, and develop targeted treatment protocols.
- **Billing considerations**: Payers may scrutinize unspecified codes more closely, potentially leading to delays or denials in reimbursement if the documentation does not adequately support the diagnosis.
- **Clinical decision-making**: Lack of specificity may hinder clinical decision-making and coordination of care, particularly in multidisciplinary settings.

---

## Conclusion

The ICD-10-CM code for a benign carcinoid tumor with an unspecified primary site is **D3A.00**. Clinicians should strive to document the specific anatomical location of the tumor whenever possible to enable more accurate coding, improve clinical management, and enhance epidemiological tracking.

---

## References

### Incidence and prevalence of neuroendocrine tumors of the lung: analysis of a US commercial insurance claims database [^6b3b00cb]. BMC Pulmonary Medicine (2018). Low credibility.

Cohort selection

Individuals at least 18 years of age were identified as having lung NET if, during a single calendar year, they had at least 1 claim from a hospital setting, or at least 2 claims from the outpatient setting, that included an ICD-9-CM diagnosis code for lung NET (that is, either 209.21 malignant carcinoid tumor of bronchus and lung, or 209.61 benign carcinoid tumor of bronchus and lung). Coding of inpatient claims in the US is usually performed by professional coders and is thus more reliable than claims from the outpatient setting, which may be recorded by a variety of staff with limited clinical training. A limitation of using claims data to estimate disease incidence is the inability to know with certainty that the first diagnosis seen in the data represents the first clinical diagnosis of the condition. Therefore, for incident cases, we required individuals to have been continuously enrolled for 3 years: the specific calendar year of diagnosis and 2 years prior, with no evidence of disease in the prior 2 years. For example, a cohort of individuals identified with lung NET in 2011 must have been enrolled during the entire 2009 to 2011 period, with their lung NET diagnosis in 2011.

---

### ICD-9-CM to ICD-10-CM codes: what? Why? How? [^fb8d01f8]. Advances in Wound Care (2013). Low credibility.

The wound care industry will gain many benefits when International Classification of Diseases (ICD)-10-Clinical Modification (CM) is implemented. One of the main benefits is that the disease classifications will be consistent with current clinical practice and medical technology advances. The new classification codes will be very granular, which means the level of specificity will greatly improve. Numerous new codes will represent more specific anatomic sites, etiologies, comorbidities, and complications, and will improve the ability to demonstrate severity of illness. For instance, the new feature of laterality is directly built into the new codes: separate codes will distinguish right, left, and bilateral, where needed. The increased granularity will provide better analysis of disease patterns and outbreak of disease. Additionally, the United States will finally be using the same diagnosis coding system as the rest of the world. This article will describe what the ICD-9-CM/ICD-10-CM codes are, why they are so important, and how clinicians and researchers will convert from ICD-9-CM to ICD-10-CM effective October 1, 2014.

---

### Incidence and prevalence of neuroendocrine tumors of the lung: analysis of a US commercial insurance claims database [^b9b686a6]. BMC Pulmonary Medicine (2018). Low credibility.

Estimates from the current study are consistent with that reported from SEER for 2012. The incidence of all NET was reported as 69.8 PMPY for 2012 and lung NET as 16.3, and our combined, adjusted estimate was 16.2 PMPY in 2014 (although this rate from the combined databases should be interpreted with caution since it obscures differences between different sources). Although these numbers are quite similar, comparing our results directly to prior estimates presents several challenges. First, we were able to use data through 2014, 2 years more recent than SEER. Second, SEER, the source of data for the 2008 and 2017 studies, is a coordinated system of population-based cancer registries located across the US. The SEER Program collects cancer incidence and survival data from 18 geographic areas, together representing about 1/4 of the US population. The insurance claims used in the present study, in contrast, are a convenience sample, albeit an extremely large one. Based on information provided by MarketScan and PharMetrics, the combined databases have claims for a geographically dispersed sample representing about 1/3 of the US population. Third, SEER includes patients of all ages; the current study only included individuals 18–64 years of age. About 95% of individuals ≥ 65 are covered by Medicare. A small number of individuals in this age group would have been available for inclusion in our study (e.g. they had commercial insurance as the primary payer, and therefore, their data were included in our databases), but they do not represent typical Medicare-age individuals, and thus were excluded from analysis. The incidence of NET is twice as high in individuals ≥ 65 compared to those 50–64. Our estimates are thus likely to understate the actual incidence and prevalence. Fourth, SEER registrars are trained and provided with software to improve their ability to accurately code reportable cancers. Claims coding is performed by a mix of care providers and professional coders. Fourth, the coding systems differ between SEER and insurance claims. SEER currently uses the International Classification of Diseases for Oncology system (ICD-O-3), whereas claims use ICD-9-CM (since 2015, ICD-10). While the systems can be mapped to each other, the mapping is not one-to-one. NET represent an unusual tumor type for which the traditional labels of benign and malignant are a poor fit. While classification has evolved considerably in the last several decades, NET are now generally described by their anatomic location (e.g. GI or lung), degree of differentiation (either "well" or "poorly"), and proliferative index (mitotic activity). Small, well differentiated NET may thus have been overlooked for inclusion into SEER. Insurance claims, relying as they do on ICD-9-CM codes, cannot be used to identify stage or tumor size. Claims data cannot be used to identify with certainty whether a case is truly incident or represents a patient who simply did not present for care for a prolonged period. We required continuous enrollment for 2 years before the first NET claim to reduce this source of uncertainty. Prevalent patients would have to have had no care for their condition for more than 2 years to have been incorrectly counted as incident cases. Other limitations of insurance claims include the lack of information on race/ethnicity or health behaviors that might explain the observed rise in lung NET. Finally, we had no information on occurrence of, timing, or cause of death, making it impossible to comment on survival.

---

### Survival outcomes for lung neuroendocrine tumors in California differ by sociodemographic factors [^a6210088]. Endocrine-Related Cancer (2024). Medium credibility.

Materials and methods

Data source

Analyses were performed using data from the CCR, part of the National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) program. The CCR is the statewide population-based cancer registry in California. This study was approved by the Institutional Review Board of the University of California, San Francisco, and the California Committee for the Protection of Human Subjects. A waiver of informed consent was granted because all data were deidentified.

Study population

The study population included all individuals aged 18 years and older in the CCR with an incident lung NET diagnosis from January 1992 through December 2019. We used tumor histology codes based on the International Classification of Disease (ICD) for Oncology, third edition and selected cases classified as either typical carcinoid (ICD-O-3 8240) or atypical carcinoid (ICD-O-3 8249) histology with an ICD-10 primary site code of the lung or bronchus (C34.0–34.9). Pulmonary atypical carcinoid cases were available beginning in 1998 due to the standardization of NET histology coding at that time. We excluded cases diagnosed at autopsy or via death certificate only. We also excluded individuals with poorly differentiated histologies, such as small- or large-cell NECs.

---

### Neuroendocrine and adrenal tumors, version 2.2021, NCCN clinical practice guidelines in oncology [^992d0ef7]. Journal of the National Comprehensive Cancer Network (2021). High credibility.

Neuroendocrine neoplasms of unknown primary — The incidence rate for NETs of an unknown primary site is 0.84 per 100,000 persons according to a SEER database analysis. Identification of the primary site can help guide treatment decisions, although there is growing overlap in the treatment of NETs arising in different organ sites. If the primary tumor cannot be identified, treatment decisions are generally guided by tumor histology.

---

### Epidemiology of neuroendocrine tumors of the appendix in the USA: a population-based national study (2014–2019) [^a46712fe]. Annals of Gastroenterology (2021). Medium credibility.

There are a few limitations to this study that largely stem from the nature of the database. Data entry and classification can be a source of potential bias and may influence the true estimates of diseases. Unfortunately, patients' information in the database is de-identified and pathology results cannot be verified for each corresponding patient, while survival data are also not available in Explorys. However, it is important to note that, compared to ICD coding, SNOMED-CT allows for more concepts to be coded per clinical document, making it more accurate in terms of documenting diagnoses and pertinent patient information. Moreover, Explorys has been validated and used in multiple specialties, including gastroenterology. Despite the aforementioned limitations, it is worth highlighting that this is the largest and one of the few studies to date to evaluate the epidemiology, and risk factors of patients with aNETs in the US population. In comparison to the SEER database, which includes only malignant pathologies, Explorys captures both benign and malignant pathologies. The data also provide a much-needed update to the existing body of population studies, which has largely focused on data from the 1980s-2000s. We also report symptoms associated with the aNET population, not commonly identified in the literature. Using multivariate analysis, several steps were implemented to avoid confounding bias.

In conclusion, this is the largest study to date utilizing a non-SEER database to evaluate the epidemiology, risk factors, predisposing medical conditions and GI symptoms associated with the development of aNETs. We found a significantly higher prevalence and incidence rates of aNETs than previously found in the literature. Additionally, our multivariate analysis determined multiple risk factors associated with aNET development. However, further research is needed to elucidate the potential mechanisms for the role of the risk factors and predisposing medical conditions identified in our study.

Summary Box

What is already known:

Gastroenteropancreatic neuroendocrine tumors (NETs) are divided into pancreatic NETs and luminal carcinoid tumors
The majority of epidemiological studies are based on the Surveillance, Epidemiology, and End Results database

What the new findings are:

The overall prevalence of NET of the appendix (aNET) was 7 per 100,000 persons, while the incidence during a single year (January 2019 to January 2020) was 0.4 per 100,000 individuals
Common symptoms associated with aNET included abdominal pain, acute appendicitis and nausea
Significant risk factors for aNET were multiple endocrine neoplasia type 1, neurofibromatosis type 1, family history of primary gastrointestinal cancer, Caucasian race, smoking, and female sex

---

### Carcinoid tumors [^bfa338d9]. Surgical Oncology Clinics of North America (2006). Low credibility.

Carcinoid tumors can present a difficult diagnostic and therapeutic dilemma. Despite their reputation as indolent tumors, they frequently metastasize and can cause significant symptomatology. The only curative therapy remains surgical resection. The prognosis and treatment of carcinoids vary based on location and histology, and therapy must be tailored to each patient.

---

### Neuroendocrine and adrenal tumors, version 2.2021, NCCN clinical practice guidelines in oncology [^233c5795]. Journal of the National Comprehensive Cancer Network (2021). High credibility.

Neuroendocrine neoplasms of unknown primary and well-differentiated, grade 3 neuroendocrine tumors are listed as distinct categories within clinical presentations and diagnosis.

---

### Neuroendocrine and adrenal tumors, version 2.2021, NCCN clinical practice guidelines in oncology [^c2496ed7]. Journal of the National Comprehensive Cancer Network (2021). High credibility.

Carcinoid syndrome — additional symptom control options — may include tumor-directed interventions to reduce burden. Other therapies that may be considered to achieve symptom control by reducing tumor burden include hepatic arterial embolization, cytoreductive surgery for liver-predominant disease, or other systemic therapy based on disease site.

---

### Sex and tumor-site differences in the association of alcohol intake with the risk of early-onset colorectal cancer [^b5e94734]. Journal of Clinical Oncology (2023). Medium credibility.

Assessment of Covariates

Participant smoking status during the study (nonsmoker, past smoker, and current smoker) and pack-years were recorded. Regular exercise was defined as ≥ 20 minutes of vigorous-intensity (≥ 3 times/wk) or ≥ 30 minutes of moderate-intensity (≥ 5 times/wk) exercise. Low income was defined as the lowest quantile of income-based insurance contributions. Comorbidities (hypertension, diabetes mellitus [DM], and dyslipidemia) were identified from the NHIS health checkup and claims data. Hypertension was defined on the basis of the International Classification of Disease, 10th Revision, Clinical Modification (ICD-10-CM) codes I10-I13 or I15 with any claim for prescription of antihypertensive medications, or a recorded blood pressure ≥ 140/90 mmHg in the index year. DM was defined as a fasting glucose level ≥ 126 mg/dL, or at least one annual claim for prescription of antidiabetic medications under the ICD-10 codes E11-E14. Dyslipidemia was defined as a serum total cholesterol level ≥ 240 mg/dL, or at least one annual claim for prescription of lipid-lowering medications under the ICD-10 code E78.

Study Outcomes

The primary outcome was the incidence of early-onset CRC diagnosed before age 50 years. CRC was defined as C18-20 on the basis of the ICD-10-CM codes (C18.0–18.4 for proximal colon cancer; C18.5–18.7 and C19.0 for distal colon cancer; C18.9 for unspecified colon cancer; C20.0 for rectal cancer) and the registration code for cancer (V193). In the subgroup analysis by tumor subsites, malignant neoplasms in overlapping sites in the colon (C18.8) were excluded because they were not specific to one location. The proportion of overlapping sites in the colon was 0.5% (46/8,314) in early-onset CRC cases. Carcinoid tumors were excluded.

---

### Impact of neuroendocrine morphology on cancer outcomes and stage at diagnosis: a UK nationwide cohort study 2013–2015 [^43f5671e]. British Journal of Cancer (2019). Medium credibility.

Incidence

The UK ASR was 8.6 per 100,000 (2013–2015 combined), 8.1 in females and 9.1 in males; 4.6 for GEP-NENs overall, the second most common gastrointestinal tumour. Incidence by other sites are listed in Table 2.

Table 2
NEN incidence, 1-year overall survival probability, multivariable analysis and mortality in the UK (2013–2015 combined)

Socioeconomic status was not available for Scotland, so deprivation for Scotland was not included see Methods

Only the most common sites are listed, for additional sites see Supplementary Table 1

ND not determined

a Excluding "death certificate only" registration i.e. date of diagnosis = date of death

b Small intestine includes: C17.0 — duodenum; C17.1 — jejunum; C17.2 — ileum; C17.3 — Meckel's diverticulum; C17.8; overlapping lesion of small intestine; C17.9 small intestine, unspecified

c MANEC includes: goblet cell carcinoid; mixed adenoneuroendocrine carcinoma; tubular adenocarcinoid tumour

d Other grade includes pathology-graded: pancreatic endocrine tumour malignant; mixed pancreatic endocrine and exocrine tumour malignant; neuroendocrine carcinoma NOS; small cell carcinoma NOS

e Other morphology includes: enterochromaffin carcinoid; gastrinoma malignant; glucagonoma malignant; insulinoma malignant; mixed pancreatic endocrine and exocrine tumour malignant; pancreatic endocrine tumour malignant; somatostatinoma malignant; tubular carcinoid; and vipoma malignant

The 2015 UK annual incidence was 8.7 per 100,000 (8.2 [95% CI, 7.8–8.5] in females and 9.2 in males [95% CI, 8.8–9.6]). It increased steadily, from 3.9 cases per 100,000 in 2001 to 7.9 per 100,000 in 2012 in England, at around 0.4 cases per 100,000 per year (Fig. 1 and Table 2), although it must be noted that these figures are from ICD-O-2 coded data so do not include morphology codes 8013 and 8249.

Fig. 1
Annual incidence (line graph) and count (bar chart) of NENs diagnosed in England 2001–2015 and the UK 2015 (cross markers)

---

### Neuroendocrine and adrenal tumors, version 2.2021, NCCN clinical practice guidelines in oncology [^b48c4b0b]. Journal of the National Comprehensive Cancer Network (2021). High credibility.

Neuroendocrine tumors of unknown primary — incidence and evaluation: The incidence rate for NETs of an unknown primary site is 0.84 per 100,000 persons according to a SEER database analysis. Identification of the primary site can help guide treatment decisions, and if the primary tumor cannot be identified, treatment decisions are generally guided by tumor histology; the initial evaluation of a patient with biopsy-proven NENs of unknown primary includes family history, clinical manifestations, laboratory studies, imaging studies, and/or immunohistochemical studies.

---

### Changing geographical patterns and trends in cancer incidence in children and adolescents in Europe, 1991–2010 (automated childhood cancer information system): a population-based study [^01024a42]. The Lancet: Oncology (2018). Medium credibility.

The cancers included in the analyses were all malignant tumours diagnosed during the complete calendar years 1991–2010, in people younger than 20 years and resident in the contributing registration areas. Several cancer types were excluded because they were not eligible for registration in all participating registries or during the whole study period: myelodysplasias (ICD-O-3 M-codes starting with 998), pilocytic astrocytoma (ICD-O-3 code M-9421), non-melanoma skin cancer (ICCC-3 subgroup XIe and XIIb with site code C44), and carcinoid tumour of the appendix (ICD-O-3 site code C18.1 and M-8240).

The data used in this study were submitted and validated during the years 2015–16. Our study design was reviewed and approved by the International Agency for Research on Cancer (IARC) Ethics Committee on June 17, 2015.

---

### Neuroendocrine and adrenal tumors, version 2.2021, NCCN clinical practice guidelines in oncology [^f046adf8]. Journal of the National Comprehensive Cancer Network (2021). High credibility.

Carcinoid syndrome — initial evaluation: Recommended evaluation includes routine biochemical evaluation with 24-hour urine or plasma 5-HIAA, a baseline echocardiogram, and imaging to assess disease progression; all recommendations are category 2A unless otherwise indicated.

---

### Occult primary, version 3.2014 [^c1971876]. Journal of the National Comprehensive Cancer Network (2014). Medium credibility.

Occult primary — additional pathologic diagnoses: Squamous cell carcinoma is listed, and for Neuroendocrine tumor, See NCCN Guidelines for Neuroendocrine and Adrenal Tumors.

---

### Neuroendocrine and adrenal tumors, version 2.2021, NCCN clinical practice guidelines in oncology [^2b05e7b5]. Journal of the National Comprehensive Cancer Network (2021). High credibility.

Neuroendocrine tumors — symptom management notes: Consider referral to pulmonary medicine for management.

---

### An analysis of rare carcinoid tumors: clarifying these clinical conundrums [^8048a2be]. World Journal of Surgery (2005). Low credibility.

Carcinoid tumors are distinct neuroendocrine neoplasms with characteristic histological, clinical, and biological properties. Though commonly associated with the gastrointestinal tract and bronchopulmonary system, a substantial number of these tumors originate in less common anatomical sites and can range from indolent, unrecognized entities to highly active, metastatic secretory tumors. Their presentation within unfamiliar locations often results in clinical confusion, and they persist as unrecognized lesions, subjecting patients to delayed, inappropriate, or ineffective treatment. The authors reviewed 13,715 carcinoid tumors identified by three consecutive registries of the National Cancer Institute (NCI) from 1950 to 1999, focusing on the anatomic sites accounting for less than one percent of all carcinoids. In addition, data from the world's literature published on carcinoid tumors within these particular anatomic locations were then analyzed with respect to incidence, clinical presentation, symptoms, diagnostic evaluation, microscopic and immunohistochemical findings, treatment strategies, and prognosis. The primary organs in which carcinoids are most commonly mistaken for some of the more conspicuous endemic tumors include the esophagus, pancreas, liver, biliary tract, gallbladder, and Meckel's diverticulum, as well as within the pelvic and otolaryngeal organs and the breast. In general, the highest proportion of "rare" carcinoids was identified in the gastrointestinal (GI) tract, with the ovary as the single most affected extra-GI site. Tumors with the worst prognosis were those that involved the pancreas (37.5%: 5-year survival) and those in the cervix (12–33%: 3-year survival). While gastrointestinal carcinoids have become a more recognized entity and thus more amenable to identification, similar lesions are often not considered in other sites and have often either been overlooked or misdiagnosed. Widespread reports of their occurrence in rare locations warrants attention. The diminution of the likelihood of inadvertently neglecting these often benign, indolent neoplasms that are well known to metastasize if unaddressed would represent an important advance. Familiarity with such unusual sites of origin will facilitate appropriate recognition and characterization of such tumors, allowing for timely intervention.

---

### Occult primary, version 3.2014 [^ca5faa90]. Journal of the National Comprehensive Cancer Network (2014). Medium credibility.

Occult primary — principles of systemic therapy: Consider systemic therapy in symptomatic patients (PS 1–2) or asymptomatic patients (PS 0) with an aggressive cancer, and base the systemic therapy regimen (listed on the following pages and others) to be used on the histologic cancer type. For neuroendocrine tumors, for poorly differentiated (high-grade or anaplastic) or small cell subtype, see NCCN Guidelines for Small Cell Lung Cancer; for well-differentiated neuroendocrine tumors, see NCCN Guidelines for Neuroendocrine and Adrenal Tumors - Carcinoid Tumors. Note: All recommendations are category 2A unless otherwise indicated.

---

### Metformin use and lung cancer survival: a population-based study in Norway [^d1e7b671]. British Journal of Cancer (2021). Medium credibility.

Study population

We identified 27,354 patients with primary LC diagnosis (Classification of Disease for Oncology, third edition (ICD-O-3) codes C33-C34), diagnosed from 01.01.2005 to 31.12.2014. Histologic subtypes, based on ICD-O-3 morphology codes, were defined as adenocarcinoma (8140/3, 8250/3, 8253/3, 8254/3, 8255/3, 8260/3, 8310/3, 8323/3, 8333/3, 8480/3, 8481/3, 8490/3, 8551/3, 8560/3, 8570/3 and 8574/3), squamous cell carcinoma (SCC) (8052/3, 8070/2, 8070/3, 8071/3, 8072/3, 8073/3, 8074/3, and 8076/3), NSCLC- Not Otherwise Specified (NOS) (8010/3, 8020/3, 8022/3, 8031/3, 8032/3, 8046/3, 8246/3, 8249/3, 8490/3, 8562/3, 8972/3 and 8973/3), large cell carcinoma (8012/3) and small cell carcinoma (SCLC) (8041/3, 8042/3, 8043/3, 8044/3, and 8045/3). Other histologies were classified as "others", and included carcinoid (8240/3, 8244/3 and 8249/3), pleomorphic carcinoma (8022/3), giant cell carcinoma (8031/3), adenoid cystic carcinoma (8200/3), large-cell neuroendocrine carcinoma (8013/3), and neoplasm malignant, including blastoma NOS (8000/3).

We excluded sarcomas, lymphomas, benign tumours (n = 424) and tumours with missing histology (n = 3118). Additionally, we excluded patients with date of diagnosis at the date of death (n = 1470), patients emigrating before diagnosis (n = 10) and patients diagnosed before the age of 20 (n = 8). This provided a final study sample of 22,324 LC patients.

---

### Neuroendocrine and adrenal tumors, version 2.2021, NCCN clinical practice guidelines in oncology [^b0c497b2]. Journal of the National Comprehensive Cancer Network (2021). High credibility.

NCCN recommendation category — This page notes: Note: All recommendations are category 2A unless otherwise indicated.

---

### Occult primary, version 3.2014 [^b2da16c0]. Journal of the National Comprehensive Cancer Network (2014). Medium credibility.

Neuroendocrine tumors — treatment of suspected neuroendocrine tumors should follow the Neuroendocrine Unknown Primary pathway of the NCCN Guidelines for Neuroendocrine and Adrenal Tumors.

---

### Effect of metastatic site on survival in patients with neuroendocrine neoplasms (NENs). An analysis of SEER data from 2010 to 2014 [^17b78fc5]. BMC Endocrine Disorders (2020). Medium credibility.

Methods

Data source

We queried the SEER database on the November 2017 submission. We specified the time frame from 2010 to 2014. We identified NENs by ICD-O3 histology codes based on prior relevant publications and the following diagnoses: Carcinoid tumor (8240), enterochromaffin cell carcinoid (8241), neuroendocrine carcinoma (8246), atypical carcinoid tumor (8249), malignant enterochromaffin-like cell tumor (8242), large cell neuroendocrine carcinoma (8013), mixed pancreatic malignant endocrine and exocrine tumor (8154), insulinoma (8151), glucagonoma (8152), malignant pancreatic endocrine tumor (8150), gastrinoma (8153), somatostatinoma (8156), vipoma (8155). We excluded any diagnosis code related to small cell lung cancer, mixed adenoneuroendocrine carcinoma and goblet cell carcinoid. We extracted the following variables: Age; sex; marital status; histology; grading; origin; site of metastasis and survival. As this is publicly available, de-identified data, no institutional review board (IRB) approval was required.

NEN classification

We relied on SEER histologic grade information to classify cases as Grade 1 /G1 or well differentiated; G2 or moderately differentiated; G3 or poorly differentiated; and G4 or undifferentiated / anaplastic. Grade 3 and 4 tumors have similar survival characteristics as per prior publications, are being treated with the same regimens and thus we grouped them together in the high grade category. For our analyses we only included patients with a single general site of metastasis (liver, lung, bone or brain) and where the grade was documented. We codified tumors of origin into the following 4 groups: Small bowel, lung, pancreatic and other/miscellaneous. Lung NENs are generally classified into typical and atypical carcinoids, large cell and small cell neuroendocrine carcinomas but for this analysis we relied on histology and grade documentation and the small cell subgroup was excluded.

---

### Carcinoid tumors [^70e4dddb]. American Family Physician (2006). Low credibility.

Carcinoid tumors are rare, slow-growing neuroendocrine neoplasms that often are indolent and may not become clinically apparent until there has been metastatic spread or evidence of carcinoid syndrome. Recent evidence has revealed that the overall incidence of carcinoid tumors has been steadily increasing, and although the disease was thought to be relatively benign, it is now considered one of increasing malignancy. Carcinoid tumors derive from different embryonic divisions of the gut: foregut carcinoid tumors commonly originate in the lungs, bronchi, or stomach; midgut carcinoid tumors in the small intestine, appendix, or proximal large bowel; and hindgut carcinoid tumors in the distal colon or rectum. Carcinoid syndrome, although rare, is most associated with midgut carcinoid tumors. The diagnosis of a carcinoid tumor often is coincidental with surgery performed for another reason. Treatment and prognosis are dependent on the location of the primary tumor and the degree and extent of metastasis at the time of diagnosis.

---

### Impact of neuroendocrine morphology on cancer outcomes and stage at diagnosis: a UK nationwide cohort study 2013–2015 [^6a1794f7]. British Journal of Cancer (2019). Medium credibility.

Limitations

Tumours with uncertain behaviour (behaviour code 1) are not consistently captured by UK cancer registries because they have historically been deemed "benign" and were not included. This means that many small and indolent NETs of the stomach, rectum, appendix and pancreas may not have been included in historical data. There is an under representation of type 1 gastric NETs and stage I and II rectal NETs — that all have excellent 5- and 10-year survivals. This under representation may be significantly skewing the survival statistics presented in this study. Also, the high incidence of G3 NECs in this study, particularly those in the lung, are not representative of previous findings. In the lung, G3 NEC is used when there has been insufficient information to classify the tumour as either small cell carcinoma or large cell neuroendocrine carcinoma. Thus, the high incidence of G3 NEC in the lung is likely to represent small cell carcinoma, large cell neuroendocrine carcinomas and mixed tumours. This misclassification of G3 NECs could also be skewing the survival analysis. This is a caveat for ongoing classification recommendations for the purposes of analysis and audit. In the future, many of these tumours will be more consistently captured with improvements in WHO terminology.

The completeness of stage was only 61% for this cohort but is improving year on year. ICD-O-3 coding was implemented in 95% of the UK in 2013 (the exception Wales in 2016), prior to this morphology codes 8013 and 8249 were not available, many of these tumours coded carcinoma or adenocarcinoma NOS (not otherwise specified). Therefore, our incidence counts are underestimates, and survival analysis limited to only 1-year.

We calculated that the missing tumours from the Welsh cohort would equate to approximately 62 from common sites. Also, an audit of the English data using data collected by the NET Centre of Excellence at King's College Hospital found 14.6% of the tumours captured were not captured by NCRAS, many behaviour 1. This would suggest the true incidence of NENs could be as high as 10 per 100,000 per year.

The capture of NENs irrespective of behaviour code, ICD-O-3 coding in Wales from 2016 and improvements in data completeness will resolve the afore mentioned issues in the future.

We were unable to calculate disease-specific survival and mortality due to death registrations by ICD-10 coding. However, recently it has become possible to link morphology to death registrations which will allow this in future studies.

---

### Neuroendocrine and adrenal tumors, version 2.2021, NCCN clinical practice guidelines in oncology [^97ca4fd6]. Journal of the National Comprehensive Cancer Network (2021). High credibility.

Carcinoid heart disease — CHD should be monitored by a cardiologist with expertise in the disease as the echocardiographic diagnosis of CHD can be challenging, and valve replacement (typically tricuspid and pulmonary) is indicated for patients with symptomatic disease.

---

### Impact of neuroendocrine morphology on cancer outcomes and stage at diagnosis: a UK nationwide cohort study 2013–2015 [^74bc8a64]. British Journal of Cancer (2019). Medium credibility.

Background

Neuroendocrine neoplasms (NENs) occur throughout the body, the most common sites including pulmonary, digestive and skin. NENs range from well-differentiated neuroendocrine tumours (NETs) to poorly differentiated carcinomas (NECs, small- and large-cell type) (World Health Organisation [WHO] Classification 2017) having varying potential, low grade and indolent to high grade and aggressive. The heterogeneous clinical presentation and biology of NENs cause significant challenges in diagnosis and management, with NENs often misdiagnosed, or diagnosis frequently delayed.

The UK cancer registries in England, Scotland, Wales and Northern Ireland systematically collect high quality histologically confirmed and validated data on all malignant cancers diagnosed. However, previous coding systems have made comprehensive isolation of NEN data for epidemiological studies impossible. Registration in the ICD-O-3 (combined topology and morphology) coding system for cases diagnosed from 2013 onward, and TNM staging of GEP-NENs from 2010have now allowed the first descriptive epidemiological study of NENs diagnosed in the UK, and the first analysis by TNM stage.

The aim of this study was to determine the epidemiology of NENs diagnosed in the UK, and to ascertain whether there are any disparities in outcomes between NENs and non-NENs at the same anatomical site.

---

### Multimodality imaging findings in carcinoid tumors: a head-to-toe spectrum [^e87b1af2]. Radiographics (2017). Low credibility.

Carcinoid tumors are a rare biologically heterogeneous group of neuroendocrine tumors with a spectrum ranging from benign indolent to aggressive metastatic tumors. They belong to the category of amine precursor uptake and decarboxylase tumors, or apudomas. The most common sites for primary locations are the gastrointestinal and respiratory tracts; however, any organ can be involved. The clinical presentation depends on location, aggressiveness, production of biologically active amines and peptides, paraneoplastic syndromes, and tendency for metastasis. Their reported age-adjusted incidence has increased in recent years, partly due to improved detection at radiologic imaging and endoscopy. Not a ll neuroendocrine cell tumors are carcinoids. Numerous systems have been proposed regarding their nomenclature and classification. Cross-sectional and functional imaging plays an important role in diagnosis, lesion characterization, and staging. Awareness of nomenclature, classification, common sites of involvement, and imaging presentation are pivotal for making the diagnosis. Knowledge of the diverse clinical, pathologic, and radiologic spectrum of carcinoid tumors involving various organs of the body is important for diagnosis and patient management. © RSNA, 2017.

---

### Conjunctivitis preferred practice pattern [^5e1c6ada]. Ophthalmology (2024). High credibility.

Conjunctivitis PPP — ICD-10 CM coding rules for seventh characters and laterality state that the applicable 7th character is required for all codes within the category and must always be the 7th character in the data field; if a code that requires a 7th character is not 6 characters, a placeholder X must be used to fill in the empty characters. For bilateral sites, the final character of the codes in the ICD-10 CM indicates laterality; if no bilateral code is provided and the condition is bilateral, separate codes for both the left and right side should be assigned, and unspecified codes should only be used when there is no other code option available. When the diagnosis code specifies laterality, regardless of which digit it is found in (i.e., 4th digit, 5th digit, or 6th digit), right is always 1, left is always 2, and bilateral is always 3.

---

### Neuroendocrine and adrenal tumors, version 2.2021, NCCN clinical practice guidelines in oncology [^67b8d995]. Journal of the National Comprehensive Cancer Network (2021). High credibility.

Recurrent disease — Disease recurrenceee pathways specify that for lung/thymus the label is "Locoregional unresectable (NET-11) or Distant metastases (NET-12)", and "Carcinoid syndrome" appears with "NET-14". Management of recurrent diseaseff references "Principles of Surgical Management of Neuroendocrine Tumors (NE-F)". In select cases, resection may be considered.

---

### Updated population-based review of carcinoid tumors [^0debf28a]. Annals of Surgery (2004). Low credibility.

Objective

To determine the population-based incidence, anatomic distribution, and survival rates of gastrointestinal carcinoid tumors.

Background

Carcinoid tumors arise from neuroendocrine cells and may develop in almost any organ. Many textbooks and articles represent single institution studies and report varying incidence rates, anatomic distribution of tumors, and patient survival rates. Population-based statistics remain largely unknown.

Methods

Data was obtained from the National Cancer Institute Surveillance, Epidemiology, and End Results program (1973 to 1997). Incidence rates, distribution, and 5-year survival rates were analyzed. Multivariate Cox regression was used to identify predictors of survival using age, race/ethnicity, gender, and tumor characteristics (size, lymph node status, and stage).

Results

Of the 11,427 cases analyzed, the average age was 60.9 years, and 54.2% were female. The overall incidence rates for carcinoid tumors have increased significantly over the past 25 years, although rates for some sites have decreased (eg, appendix). The gastrointestinal tract accounted for 54.5% of the tumors. Within the gastrointestinal tract, the small intestine was the most common site (44.7%), followed by the rectum (19.6%), appendix (16.7%), colon (10.6%), and stomach (7.2%). The 5-year survival rates for the most common gastrointestinal sites were stomach (75.1%), small intestine (76.1%), appendix (76.3%), and rectum (87.5%).

Conclusions

Using national, population-based cancer registry data, this study demonstrates that (1) incidence rates for carcinoid tumors have changed, (2) the most common gastrointestinal site is not the appendix (as is often quoted), but the small intestine, followed in frequency by the rectum, and (3) survival rates differ between individual anatomic sites.

---

### Neuroendocrine and adrenal tumors, version 2.2021, NCCN clinical practice guidelines in oncology [^a36a918e]. Journal of the National Comprehensive Cancer Network (2021). High credibility.

Carcinoid syndrome — surveillance: Echocardiogram every 1–3 y or as clinically indicated for patients without carcinoid heart disease (CHD) and at least annually for patients with established CHD. Multiphasic abdomen/pelvis CT or MRI is described every 12 wk–12 mo, and chest CT (± contrast) as clinically indicated; multiphasic imaging studies are performed with IV contrast in arterial and portal venous phases.

---

### Impact of neuroendocrine morphology on cancer outcomes and stage at diagnosis: a UK nationwide cohort study 2013–2015 [^5f9bb23d]. British Journal of Cancer (2019). Medium credibility.

Tumour classification

NENs were defined by the WHO 2015 classification excluding diffuse pulmonary neuroendocrine hyperplasia. Tumours occurring at all anatomical sites between C00 and C80 according to the 10th edition of the WHO International Classification of Disease (ICD-10) codes were included, and morphology codes included 8013 (excluding lung [C34 and C78]), 8041–8045 (excluding lung), 8150–8158, 8240–8247, 8249 and 9091 according to the WHO International Classification of Diseases for Oncology, 3rd Edition (ICD-O-3). All were behaviour code 3 (malignant), 6 (metastatic) or 9 (malignant, uncertain whether primary or metastatic).

Tumours were staged according to the American Joint Committee on Cancer (AJCC) TNM staging for NENsand the European Neuroendocrine Tumor Society (ENETS) recommendations for the staging of GEP-NENsand graded using the ENETS grading system (WHO 2010) for GEP-NENs, – or according to pathological grading of differentiation for other sites. Ki-67 status was not uniformly captured and is not recognised yet in many organ systems. Due to this being a registry study, we were unable to revisit each tissue specimen to acquire it, most grades were therefore based on a morphology of "poorly differentiated" or "well-differentiated" so grade 1 and grade 2 were combined to reduce inaccuracies. Tumour grades were classified: grade 1 and grade 2 combined — NET G1/G2 (functioning tumours including insulinomas, glucagonomas etc. with morphology codes 8150–8153, 8155–8158 and tumours with morphology codes 8240–8242, 8249, and 9091); grade 3 — NEC G3 (large cell carcinoma, small cell carcinoma, combined small cell carcinoma, neuroendocrine carcinoma NOS with morphology codes 8013, 8041–8045, and 8246); Mixed Adeno-Neuroendocrine Carcinoma (MANEC) (Now known as 'goblet cell adenocarcinomas') goblet cell carcinoid, mixed adenoneuroendocrine carcinoma, tubular adenocarcinoid tumour with morphology codes 8243–8245); and "other" (pancreatic endocrine tumour malignant, mixed pancreatic endocrine and exocrine tumour malignant, and Merkel cell carcinoma morphology codes 8150, 8154 and 8247, respectively).

---

### Neuroendocrine and adrenal tumors, version 2.2021, NCCN clinical practice guidelines in oncology [^01027f3c]. Journal of the National Comprehensive Cancer Network (2021). High credibility.

Neuroendocrine tumors (NETs) — U.S. epidemiology and temporal trends indicate that an analysis of the SEER database estimated the incidence of NETs in the United States was 6.98 cases per 100,000 people in the year 2012, and this analysis suggested that the incidence of NETs is increasing with a prevalence that may exceed 170,000; other independent analyses found that the incidence of GI NETs increased from 1975 to 2008, with reasons for the increase unclear although improved diagnosis and classification is cited as one factor.

---

### Incidence and prevalence of neuroendocrine tumors of the lung: analysis of a US commercial insurance claims database [^2f392523]. BMC Pulmonary Medicine (2018). Low credibility.

Design and data source

This was a descriptive epidemiological study using insurance claims data from January 1, 2009 to December 31, 2014. The data were from two large US commercial claims databases: Truven Health MarketScan Commercial Claims and Encounters Database, and IMS Health PharMetrics. The MarketScan database has information from more than 100 payers of private health insurance for employees and their dependents, covering more than 25 million lives annually. The PharMetrics database is a nonpayer owned integrated claims database of commercial insurers that includes medical and pharmacy claims for more than 70 million unique individuals across the US. Both databases contain de-identified adjudicated medical claims (e.g. inpatient and outpatient services) and pharmacy claims (e.g. outpatient prescriptions).

Payments to providers, healthcare facilities, and pharmacies for the 66% of the US population with commercial insurance are contingent on submission of claims for services. These insurance claims contain information about diagnoses (International Classification of Diseases, 9th Revision, Clinical Modification [ICD-9-CM] diagnosis codes) and procedures (Current Procedural Terminology 4 [CPT-4] and ICD-9-CM procedure codes). Information on each physician visit, medical procedure, hospitalization, drug dispensed, date of service, number of days of medication supplied, test performed, as well as complete payment information, is available for covered individuals from their insurance claims. Available patient demographic information is limited to age, gender, and broad geographic region. An "enrollment" file provides information on each individuals' dates of coverage — the dates for which we can find their insurance claims. No information is available about individuals for dates outside their dates of enrollment. Information about death, including date or cause, is not available. Privacy restrictions make it impossible to contact patients or review their detailed medical records to obtain additional clinical or demographic information such as health behaviors, tumor size/stage, or race/ethnicity. In the US, individuals may change their insurance coverage over time, and thus the number of individuals enrolled in a given plan changes from year to year. For this study, we were provided the total number of individuals in each database each year, broken down by age and gender. Both databases contain a limited number of individuals ≥ 65 years old. US individuals ≥ 65 who have commercial insurance are not representative of the broader age group, a large majority of whom are insured through the Federal Medicare program. Therefore, the analysis was restricted to individuals < 65. Analyses were performed separately using each database and results were compared to check consistency. As the data were de-identified, this study was considered exempt from approval by the Institutional Review Board.

---

### Neuroendocrine and adrenal tumors, version 2.2021, NCCN clinical practice guidelines in oncology [^71e4fc7d]. Journal of the National Comprehensive Cancer Network (2021). High credibility.

Neuroendocrine neoplasms of unknown primary — classification and routing specify to indicate well- or poorly differentiated status, with branches for well-differentiated grade 1/2 to Management of Locoregional Advanced Disease and/or Distant Metastases of the Gastrointestinal Tract (NET-9) and for well-differentiated grade 3 to Management of Well-Differentiated Grade 3 Locoregional Disease (WDG3-2) and Locally Advanced/Metastatic Disease: Favorable Biology (WDG3-3) or Locally Advanced/Metastatic Disease: Unfavorable Biology (WDG3-4). When a primary is identified, see specific tumor type (CP-1). Additional notes state to treat presumptively as gastroenteropancreatic (GEP) NETs if it is unknown primary and to consider small bowel primary tumor based on symptoms and associated radiologic findings.

---

### Epidemiology and classification of gastroenteropancreatic neuroendocrine neoplasms using current coding criteria [^1af26778]. The British Journal of Surgery (2016). Low credibility.

A concern related to epidemiological figures from cancer registries (such as the National Cancer Institute Surveillance, Epidemiology and End Results (SEER) database and the Cancer Registry of Norway) is that the recording of NEN is usually restricted to 'malignant carcinoids', thereby disregarding benign tumours and NEN with uncertain malignant potential, as noted by Hauso and colleagues 45. A rather low, although increasing, annual incidence of GEP‐NEN of 2.38 per 100 000 (USA 2000; for interval 2000–2004), as can be calculated from that study 45, is explained mainly by under‐reporting to the registry.

Data collection over long intervals introduces bias of disease definitions and classifications 22. A lower incidence of GEP‐NEN is usually reported from other series. A French study 15 found an annual age‐adjusted (world) incidence rate associated with malignant digestive NEN (pancreatic lesions included) of 0.76 per 100 000 men and 0.50 per 100 000 women. The study had a higher median age and a smaller proportion of appendiceal tumours than the present investigation. Although an increasing incidence was observed (1976–1999), differences between these two studies can be explained mainly by the fact that only malignant tumours were included in the French analysis 16. A prospective 1‐year audit of GEP‐NEN from Austria 13 reported an annual age‐adjusted incidence rate (USA 2000) of 2.99 per 100 000 inhabitants. Tumours were most frequently located in the stomach, whereas the small bowel was less commonly affected. Although the authors assumed a high degree of completeness of the data, one‐quarter of the 41 institutions involved did not report any patients, suggesting possible detection bias. Finally, a study from the Netherlands Cancer Registry 37 reported an age‐standardized (with respect to European standardized rate) increase in the incidence of NEN from 2.1 in 1990 to 4.9 per 100 000 inhabitants in 2010. Although this supports an increasing incidence, the lower reported incidence is again likely to be explained by a reporting bias towards malignant disease.

---

### Symptom management for well-differentiated gastroenteropancreatic neuroendocrine tumors: ASCO guideline [^1d535dcf]. JCO Oncology Practice (2025). High credibility.

ASCO GEP-NET symptom management guideline — scope and clinical question: Target population is patients with well-differentiated grade 1 (G1)-grade 3 (G3) metastatic gastroenteropancreatic neuroendocrine tumors (GEP-NETs) with symptoms from hormone excess or tumor bulk, and the guideline addresses the question, "What are the recommended treatment options for management of symptoms of functional GEP-NETs, including carcinoid syndrome, carcinoid heart disease, and functional panNETs?".

---

### NCCN guidelines® insights: ovarian cancer / fallopian tube cancer / primary peritoneal cancer, version 3.2024 [^7e4d8cc7]. Journal of the National Comprehensive Cancer Network (2024). High credibility.

WHO histologic classification — ovarian, fallopian tube, and primary peritoneal entities are categorized with behavior codes, where Behavior is coded 0 for benign tumors; 1 for unspecified, borderline, or uncertain behavior; 2 for carcinoma in situ and grade III intraepithelial neoplasia; 3 for malignant tumors, primary site. Sex cord-stromal tumors include Pure Sex Cord Tumors such as Adult granulosa cell tumor of the ovary 3, Granulosa cell tumor, juvenile 1, Sertoli cell tumor NOS 1, and Sex cord tumor with annular tubules 1, and Mixed Sex Cord-Stromal Tumors where Sertoli-Leydig cell tumor, poorly differentiated 3 contrasts with Sertoli-Leydig cell tumor, retiform 1 and Sex cord tumor NOS 1; Pure Stromal Tumors list Steroid cell tumor NOS 0, Steroid cell tumor, malignant 3, and Fibrosarcoma NOS 3. Germ cell tumors include Teratoma, benign 0, Immature teratoma NOS 3, Dysgerminoma 3, Yolk sac tumor NOS 3, Embryonal carcinoma NOS 3, Choriocarcinoma NOS 3, and Mixed germ cell tumor 3; Monodermal Teratoma & Somatic-type Tumors from Dermoid Cyst include Struma ovarii, NOS 0, Struma ovarii, malignant 3, Strumal carcinoid 1, Teratoma with malignant transformation 3, and Cystic teratoma NOS 0. Germ Cell- Sex Cord-Stromal Tumors include Gonadoblastoma 1 and Mixed germ cell- sex cord-stromal tumor, NOS 1; Miscellaneous Tumors include Adenoma of rete ovarii 0, Adenocarcinoma of rete ovarii 3, Wolffian tumor 1, Solid pseudopapillary tumor of ovary 1, Small cell carcinoma, hypercalcemic type 3, Small cell carcinoma, large cell variant 3, and Wilms tumor 3. Tumor-like Lesions listed as benign include Follicle cyst 0, Corpus luteum cyst 0, Stromal hyperplasia and hyperthecosis 0, and Leydig cell hyperplasia 0. Note: All recommendations are category 2A unless otherwise indicated.

---

### Primary open-angle glaucoma suspect preferred practice pattern® guidelines [^c5bd4139]. Ophthalmology (2016). Medium credibility.

ICD-10-CM laterality and 7th-character rules — Certain ICD-10 CM categories have applicable 7th characters, the 7th character must always be the 7th character in the data field, and a placeholder X is required if a code needing a 7th character is not 6 characters. For bilateral sites, the final character of the code indicates laterality; if no bilateral code is provided and the condition is bilateral, separate codes for both the left and right side should be assigned, with unspecified codes used only when there is no other code option available. When laterality is specified in the diagnosis code, Right is always 1, Left is always 2, and Bilateral is always 3.

---

### Symptom management for well-differentiated gastroenteropancreatic neuroendocrine tumors: ASCO guideline [^30594ccb]. JCO Oncology Practice (2025). High credibility.

ASCO guideline — symptom management for well-differentiated gastroenteropancreatic neuroendocrine tumors (NETs) develops recommendations for patients with well-differentiated grade 1 to grade 3 metastatic disease and focuses on grade 1 (G1) to grade 3 (G3) NETs, which account for approximately 80%-90% of neuroendocrine neoplasms (NENs). The evidence base informing the guidance included eight guidelines, 19 systematic reviews, and three randomized controlled trials (RCTs). Recommendations are included for carcinoid syndrome, carcinoid heart disease and carcinoid crisis, and functional pancreatic NET syndromes, and provide guidance for surgical management, liver-directed therapy, systemic therapy options, and palliative care, with limited guidance for sequencing of interventions.

---

### Neuroendocrine carcinomas (carcinoid, atypical carcinoid, small cell carcinoma, and large cell neuroendocrine carcinoma): current concepts [^d9290ba7]. Hematology/Oncology Clinics of North America (2007). Low credibility.

Neuroendocrine carcinomas are ubiquitous neoplasms that may occur anywhere in the human body. A unifying concept regarding the classification of these tumors has been controversial. Although most neuroendocrine neoplasms occur in the gastrointestinal tract, current concepts regarding classification and nomenclature are being driven by studies of thoracic tumors. One issue that has been put forward to keep separate nomenclatures for these tumors in different organ systems is the different clinical behavior of these neoplasms in different systems. The most important aspect regarding this group of tumors is the fact that they should be considered neoplasms capable of local recurrence and distant metastasis. Close clinical correlation and appropriate treatment are important to improve the survival rate in this group of patients.

---

### Health policy basics: implementation of the international classification of disease, 10th revision [^489ad2ef]. Annals of Internal Medicine (2015). Low credibility.

The International Classification of Diseases (ICD) standardizes diagnostic codes into meaningful criteria to enable the storage and retrieval of information regarding patient care. Whereas other countries have been using ICD, 10th Revision (ICD-10), for years, the United States will transition from ICD, Ninth Revision, Clinical Modification (ICD-9-CM), to ICD-10, on 1 October 2015. This transition is one of the largest and most technically challenging changes that the medical community has experienced in the past several decades. This article outlines the implications of moving to ICD-10 and recommends resources to facilitate the transition.

---

### Neuroendocrine and adrenal tumors, version 2.2021, NCCN clinical practice guidelines in oncology [^1ffc96d7]. Journal of the National Comprehensive Cancer Network (2021). High credibility.

Neuroendocrine tumors of the pancreas (well-differentiated grade 1/2), locoregional nonfunctioning disease — primary non-metastatic management: For resectable disease, Small (≤ 1 cm) tumors list Observation. For tumors > 1 to ≤ 2 cm, the pathway lists Observation in select cases or Pancreatectomy or Enucleation in select cases. For Larger (> 2 cm), invasive, or node-positive tumors, Pancreatectomy is listed. Observation can be considered for small (≤ 2 cm), low-grade, incidentally discovered, nonfunctional tumors with the decision based on estimated surgical risk, site of tumor, and patient comorbidities; PanNETs that are 1–2 cm have a small, but real risk of lymph node metastases, therefore lymph node resection should be considered. Surveillance is directed to PanNET-11, and All recommendations are category 2A unless otherwise indicated.

---

### Carcinoid tumors [^92600156]. The Surgical Clinics of North America (2009). Low credibility.

Carcinoid tumors, which arise from the enterochromaffin cells of the gastrointestinal tract, encompass a diverse group of neoplasms. Once thought to be "carcinoma-like", these neoplasms exhibit a biologic behavior that varies from an indolent, benign course to an aggressive, rapidly progressive, and deadly disease. Today the term carcinoid is reserved for neuroendocrine tumors arising from the small bowel or neuroendocrine tumors that can cause carcinoid syndrome. This newer terminology has yet to be universally adopted, adding to the confusion in the literature. For the general surgeon there are several "carcinoid" tumors that he or she must be familiar with because many of these lesions are encountered during emergency laparotomies or incidentally discovered during investigation for vague abdominal pain. This review focuses on the gastrointestinal neuroendocrine tumors that general surgeons are likely to encounter during their career.

---

### The tragedy of the implementation of ICD-10-CM as ICD-10: is the cart before the horse or is there a tragic paradox of misinformation and ignorance? [^71b70a4c]. Pain Physician (2015). Low credibility.

The forced implementation of ICD-10-CM (International Classification of Diseases, Tenth Revision, Clinical Modification) codes that are specific to the United States, scheduled for implementation October 1, 2015, which is vastly different from ICD-10 (International Classification of Diseases, Tenth Revision), implemented worldwide, which has 14,400 codes, compared to ICD-10-CM with 144,000 codes to be implemented in the United States is a major concern to practicing U.S. physicians and a bonanza for health IT and hospital industry. This implementation is based on a liberal interpretation of the Health Insurance Portability and Accountability Act (HIPAA), which requires an update to ICD-9-CM (International Classification of Diseases, Ninth Revision, Clinical Modification) and says nothing about ICD-10 or beyond. On June 29, 2015, the Supreme Court ruled that the Environmental Protection Agency unreasonably interpreted the Clean Air Act when it decided to set limits on the emissions of toxic pollutants from power plants, without first considering the costs on the industry. Thus, to do so is applicable to the medical industry with the Centers for Medicare and Medicaid Services (CMS) unreasonably interpreting HIPAA and imposing existent extensive regulations without considering the cost. In the United States, ICD-10-CM with a 10-fold increase in the number of codes has resulted in a system which has become so complicated that it no longer compares with any other country. Moreover, most WHO members use the ICD-10 system (not ICD-10-CM) only to record mortality in 138 countries or morbidity in 99 countries. Currently, only 10 countries employ ICD-10 (not ICD-10-CM) in the reimbursement process, 6 of which have a single payer health care system. Development of ICD-10-CM is managed by 4 non-physician groups, known as cooperating parties. They include the Centers for Disease Control and Prevention (CDC), CMS, the American Hospital Association (AHA), and the American Health Information Management Association (AHIMA). The AHIMA has taken the lead with the AHA just behind, both with escalating profits and influence, essentially creating a statutory monopoly for their own benefit. Further, the ICD-10-CM coalition includes 3M which will boost its revenues and profits substantially with its implementation and Blue Cross Blue Shield which has its own agenda. Physician groups are not a party to these cooperating parties or coalitions, having only a peripheral involvement. ICD-10-CM creates numerous deficiencies with 500 codes that are more specific in ICD-9-CM than ICD-10-CM. The costs of an implementation are enormous, along with maintenance costs, productivity, and cash disruptions.

---

### European Neuroendocrine Tumor Society (ENETS) 2022 guidance paper for carcinoid syndrome and carcinoid heart disease [^68e29f60]. Journal of Neuroendocrinology (2022). Medium credibility.

1 MATERIALS AND METHODS

Data regarding the diagnosis, management, and follow‐up of carcinoid syndrome (CS) and carcinoid heart disease (CHD) were identified by searches of the MEDLINE database using specific terms in human studies: CS; CHD; screening; epidemiology; diagnosis; treatment; prognosis. The search results were supplemented by manual searching of relevant journals, reference lists in key articles and other appropriate documents, and expert opinion. All recommendations are offered on the basis of the best available evidence, supplemented by the authors' experiences in managing CS and CHD. Each recommendation for treatment will have a level of evidence and grade of recommendation as per the GRADE system (adapted in Infectious Disease society of US Public Health Service grading system)(Tables 1 and 2). A list of abbreviations is provided at the end of the manuscript.

TABLE 1
Level of therapies/intervention for recommendation

TABLE 2
Level of evidence and grade of recommendation as specified in the GRADE criteria

---

### Neuroendocrine and adrenal tumors, version 2.2021, NCCN clinical practice guidelines in oncology [^17c06574]. Journal of the National Comprehensive Cancer Network (2021). High credibility.

Neuroendocrine and adrenal tumors — imaging for suspected locoregional advanced and/or distant metastatic disease notes that imaging recommendations include multiphase technique CT or MRI at baseline and to assess disease progression; when evaluating locoregional advanced and/or metastatic NETs of the GI tract, lung, and thymus, or for suspected carcinoid syndrome, multiphasic abdomen/pelvis CT or MRI with IV contrast are recommended, and chest CT scans with or without contrast are recommended as clinically indicated; the most common sites of metastases from intestinal NETs include regional/mesenteric lymph nodes, liver, and bones.

---

### Neuroendocrine and adrenal tumors, version 2.2021, NCCN clinical practice guidelines in oncology [^ff1b76f6]. Journal of the National Comprehensive Cancer Network (2021). High credibility.

NCCN Neuroendocrine and Adrenal Tumors — epidemiology in the United States — notes increasing incidence of neuroendocrine tumors (NETs), with an analysis of the SEER database estimating the incidence at 6.98 cases per 100,000 people in the year 2012 and indicating that the prevalence of individuals with NETs in the United States may exceed 170,000; other independent analyses found that the incidence of gastrointestinal (GI) NETs increased from 1975 to 2008.

---

### Symptom management for well-differentiated gastroenteropancreatic neuroendocrine tumors: ASCO guideline [^41c695c9]. JCO Oncology Practice (2025). High credibility.

Carcinoid heart disease — surgical management advises cardiology referral at the first sign of valve involvement, referral for valve surgery for severe regurgitation when symptoms or echocardiographic evidence of right ventricular dysfunction develop with consideration of disease status and systemic therapy options, closure of patent foramen ovale at valve surgery, and preference for biological valve prostheses with valve choice at the cardiac surgeon's discretion.

---

### Occult primary, version 3.2014 [^1f3e53dd]. Journal of the National Comprehensive Cancer Network (2014). Medium credibility.

Occult primary adenocarcinoma — recommendation category is stated as category 2A unless otherwise indicated.

---

### Which ICD-9 codes were assigned for malignant mesothelioma in the mortality data in the United States before the ICD-10 was introduced? [^837f0403]. American Journal of Industrial Medicine (2022). Medium credibility.

Background

Malignant mesothelioma (MM) is rare and fatal; survival in most cases is only about one year. Mortality rate is, therefore, a good proxy measure of incidence rate. However, the specific International Classification of Diseases (ICD) code for MM was not available until the Tenth Revision ICD (ICD-10). Little is known on which Ninth Revision ICD (ICD-9) codes were assigned for MM in the ICD-9 era.

Methods

We used a 1996 double-coded mortality file compiled by the National Center for Health Statistics to calculate the detection rate (DR) and confirmation rate (CR) of selected ICD-9 codes.

Results

Of 2386 decedents whose underlying cause of death was MM (ICD-10 code C45), the DR (deaths) of corresponding ICD-9 code was 57% (1365) for code 199 "malignant neoplasm without specification of site"; 19% (448) for code 162.9 "malignant neoplasm of trachea, bronchus, and lung, unspecified"; 13% (310) for code 163 "malignant neoplasm of pleura"; and 11% (271) for other codes. The CR (deaths) for the aforementioned three ICD-9 codes were 4.0% (1365/33,942), 0.3% (448/150,342), and 70.8% (310/438), respectively.

Conclusions

The three ICD-9 codes (199, 162.9, and 163) were the most commonly used codes for MM and composed nine-tenths of all MM deaths in the years before the ICD-10 was introduced. Using only ICD-9 code 163, the code most often used as the surrogate measure of MM in mortality studies in the ICD-9 era, capture may have been only 13% of all MM deaths in the US, and the estimated number of MM deaths missed in 1996 would be 2086.

---

### Symptom management for well-differentiated gastroenteropancreatic neuroendocrine tumors: ASCO guideline [^1a9c783c]. JCO Oncology Practice (2025). High credibility.

GEP-NET epidemiology and functional syndromes — key figures: In the United States, the age-adjusted incidence of neuroendocrine tumors (NETs) per 100,000 persons rose from 4.9 in 2000 to 8.19 in 2018. In a study of data gathered between 2000 and 2011, 32.4% of 2,211 patients with small bowel NETs had symptoms of carcinoid syndrome. Approximately 10%-20% of patients with pancreatic NETs (panNETs) are reported to have one of several clinical syndromes as a result of hormone excess.

---

### Symptom management for well-differentiated gastroenteropancreatic neuroendocrine tumors: ASCO guideline [^aafeb9b4]. JCO Oncology Practice (2025). High credibility.

Evidence quality and recommendation rating definitions — ASCO guideline describe evidence quality as High ("We are very confident that the true effect lies close to that of the estimate of the effect"), Moderate ("We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different"), Low ("Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect"), and Very Low ("We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of the effect"); the strength of recommendation is defined as Strong (the desirable effects outweigh the undesirable effects, and "All or almost all informed people would make the recommended choice for or against an intervention"), Conditional/weak (the desirable effects probably outweigh the undesirable effects but "appreciable uncertainty exists" and "Most informed people would choose the recommended course of action, but a substantial number would not"), and Good practice statement ("Good practice statements represent the consensus of the Expert Panel and are used when high-quality indirect evidence is available, but it would not be a good use of the Expert Panel's resources to conduct a formal systematic review").

---

### Neuroendocrine and adrenal tumors, version 2.2021, NCCN clinical practice guidelines in oncology [^ba0d5c77]. Journal of the National Comprehensive Cancer Network (2021). High credibility.

Cardiac monitoring and imaging in carcinoid syndrome — An echocardiogram should be performed every 1 to 3 years or as clinically indicated for patients without CHD, and at least annually for established CHD; tricuspid regurgitation was diagnosed in 59% in one study, and CHD was more likely with 5‑HIAA ≥ 300 μmol (57 mg) over 24 hours and ≥ 3 flushing episodes/day; surveillance CT or MRI every 12 weeks to 12 months and chest CT should be performed as clinically indicated.

---

### Neuroendocrine tumours in rare sites: differences in nomenclature and diagnostics-a rare and ubiquitous histotype [^93959ff3]. Journal of Clinical Pathology (2016). Low credibility.

The diagnosis of neuroendocrine tumours in typical sites, as gastrointestinal tract and lung, is based upon well-coded criteria that have become familiar to most of the pathologists. Much more difficult is the recognition and allocation of proper nomenclature to be referred to the same histotype in locations where these tumours have a lower incidence. The aim of our review was to provide a quick handbook of the main diagnostic pitfalls known in literature that can interpose in the histopathological examination of neuroendocrine tumours in rare sites (urinary system and male genital organs, female genital organs, head and neck and breast).

---

### Symptom management for well-differentiated gastroenteropancreatic neuroendocrine tumors: ASCO guideline [^f9439963]. JCO Oncology Practice (2025). High credibility.

Carcinoid heart disease — team-based care and screening recommends a multidisciplinary team approach at a higher-volume neuroendocrine tumor (NET) specialty center and advises that in patients without carcinoid heart disease on initial echocardiogram, repeat echocardiography should be performed every 1–2 years or with clinical change or rising B‑type natriuretic peptide (BNP), and notes that BNP should be assessed at baseline and follow-up for appropriate patients.

---

### Occult primary, version 3.2014 [^49859920]. Journal of the National Comprehensive Cancer Network (2014). Medium credibility.

Occult primary — recommendation category notes that all recommendations are category 2A unless otherwise indicated.

---

### Prevalence and incidence of fractures in patients with nonfunctional adrenal tumors [^82beaadd]. JAMA Network Open (2024). High credibility.

Study Design and Setting

This cohort study was approved by the Swedish Ethical Review Authority, which did not require informed consent due to the retrospective nature of the study. Part of this cohort has been used in previous studies. The study followed the Strengthening the Reporting of Observational Studies in Epidemiology reporting guideline for cohort studies.

This population-based, retrospective cohort study was conducted in patients with NFATs diagnosed in Sweden between January 1, 2005, and December 31, 2019. The Swedish personal identity number was used for data linkage among several national registers. The National Patient Register, containing all inpatient and specialist outpatient care, was used to identify International Statistical Classification of Diseases and Related Health Problems, Tenth Revision (ICD-10) codes from 1997 until 2019. The Cause of Death Register was used to identify individuals who had died between 2005 and 2020. Drug dispensations were identified using the Anatomical Therapeutic Chemical (ATC) codes and the Swedish Prescribed Drug Register from mid-2005 until 2019. All individuals with a first-ever ICD-10 code of D44.1 (neoplasm of uncertain behavior of adrenal gland) and/or D35.0 (benign neoplasm of adrenal gland) between 2005 and 2019 were identified, and the index date for each individual was set as the date of the first of 1 of these diagnoses. The Total Population Register was used to randomly select age- and sex-matched controls at a 4:1 ratio. Any individuals with a known malignant tumor of any kind (ie, any ICD-10 C code) diagnosed since 1997 up to the index date were excluded. Any patients with a diagnosis of hormonal activity, such as Cushing syndrome (ICD-10 code E24), congenital adrenal hyperplasia (ICD-10 code E25), primary aldosteronism (ICD-10 code E26), and pheochromocytoma (ICD-10 code E27.5), from 1997 until 2019 were excluded from both groups. By excluding all hormonally active lesions in the current study, we focused on only NFATs. However, some cases of MACS may have been included because they may not have received the ICD-10 code E24. Fractures, osteoporosis medications (antiresorptive and anabolic medications), and confounding factors were identified using the ICD-10 and ATC codes (eTable 1 in Supplement 1). Fragility fractures were defined as distal arm, vertebral, or hip fractures. Given that many fragility fractures occur during a fall on the same level, these fractures were also identified. The cohort was stratified by sex and at 50 years of age because menopause usually commences at approximately 50 years of age in women.

---

### Occult primary, version 3.2014 [^835bb574]. Journal of the National Comprehensive Cancer Network (2014). Medium credibility.

Occult primary — recommendation category label: All recommendations are category 2A unless otherwise indicated.

---

### ICD-10: history and context [^7f4e391d]. AJNR: American Journal of Neuroradiology (2016). Low credibility.

In recent months, organized medicine has been consumed by the anticipated transition to the 10th iteration of the International Classification of Disease system. Implementation has come and gone without the disruptive effects predicted by many. Despite the fundamental role the International Classification of Disease system plays in health care delivery and payment policy, few neuroradiologists are familiar with the history of its implementation and implications beyond coding for diseases.

---

### Occult primary, version 3.2014 [^299b9b41]. Journal of the National Comprehensive Cancer Network (2014). Medium credibility.

Occult primary recommendations — "All recommendations are category 2A unless otherwise indicated".

---

### Follow-up and surveillance of the patient with lung cancer after curative-intent therapy: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines [^c957cf2c]. Chest (2013). Medium credibility.

Bronchial carcinoid tumor — bronchoscopic resection and surveillance outcomes indicate that bronchoscopic resection, reserved for typical carcinoid tumors with a small, < 1-cm base and no extraluminal growth or nodal involvement, may provide prolonged recurrence-free survival; in a prospective series of 72 patients (57 typical, 15 atypical), initial bronchoscopic management eradicated tumor in 33 (46%), follow-up included flexible bronchoscopy plus high-resolution CT and biopsy within 6 weeks, then every 6 months for 2 years and annually thereafter, and surgery was required in 37 cases (including 11 of 15 atypical), with two delayed recurrences at 9 and 10 years and, at a median follow-up of 65 months, only one death was tumor related.

---

### Risk of second cancers in patients with colorectal carcinoids [^50bb882a]. Diseases of the Colon and Rectum (2002). Low credibility.

Introduction

It is often stated that patients with colorectal carcinoid tumors have an increased risk of developing other malignancies. However, this risk has not been conclusively documented. A comprehensive evaluation is needed to more thoroughly assess the risk of second cancers in patients with colorectal carcinoids.

Methods

A search of the National Cancer Institute Surveillance, Epidemiology, and End Result database from 1973 to 1996 revealed 2,086 patients with colorectal carcinoids. This subset of patients was examined for occurrence of second cancers. The observed incidence of cancer for each site was compared with the expected incidence based on the gender-adjusted and age-adjusted cancer rates in the remaining Surveillance, Epidemiology, and End Result file. A Poisson distribution probability was used to determine the significance of these comparisons.

Results

Patients with colorectal carcinoids had an increased rate of cancer in the colon and rectum (P < 0.001), small bowel (P < 0.001), esophagus/stomach (P = 0.02), lung/bronchus (P < 0.001), urinary tract (P = 0.005), and prostate (P < 0.001), when compared with a control population. Most of the gastrointestinal tract cancers were synchronous cancers, whereas lesions outside the gastrointestinal tract were most commonly metachronous tumors.

Conclusions

A significantly increased risk of synchronous colorectal, small-bowel, gastric, and esophageal cancers and metachronous lung, prostate, and urinary tract neoplasms is clearly demonstrated. After the diagnosis of colorectal carcinoid tumors, patients should undergo appropriate screening and surveillance for cancer at these sites.

---

### Primary malignant lung tumors in children: a report from the Australian childhood cancer registry, 1983–2015 [^983b078b]. Pediatric Pulmonology (2020). Medium credibility.

Lung cancers in children under the age of 15 are very uncommon, with a scarcity of literature describing patient characteristics and survival. This study assessed first primary malignant cancers occurring in the trachea, bronchus, or lung (International Classification of Diseases for Oncology, 3rd edition [ICD-O-3] codes C33-C34) for the period 1983–2015, using data from the population-based Australian Childhood Cancer Registry. Variables of interest included morphology, sex, age group, and metastatic status at diagnosis. Mode of treatment was also assessed where possible. The Kaplan-Meier method was used to calculate 5-year observed survival. Of the 53 in-scope patients, almost half (n = 23, 43%) were diagnosed with pleuropulmonary blastoma and a further 8 (15%) had a carcinoid tumor. Few of the patients with details available on stage at diagnosis (n = 7 of 43, 16%) presented with metastatic disease. Surgical excision was the most common treatment (30 of 37 children, 81%), with two-thirds (n = 28 of 43, 65%) receiving chemotherapy. Five-year observed survival was estimated to be 74% (95% CI = 61%-85%). Our results represent one of the largest and most complete population-based cohorts of children with primary malignant lung cancers available to date. Detection of childhood lung cancer can be difficult due to the rarity of this disease and symptoms that are typically nonspecific.

---

### Carcinoid tumors [^94b3fb48]. The Oncologist (2008). Low credibility.

Carcinoid tumors are rare, slow-growing neuroendocrine tumors arising from the enterochromaffin cells disseminated throughout the gastrointestinal and bronchopulmonary systems. Though they have been traditionally classified based on embryologic site of origin, morphologic pattern, and silver affinity, newer classification systems have been developed to emphasize the considerable clinical and histopathologic variability of carcinoid tumors found within each embryologic site of origin. These neoplasms pose a diagnostic challenge because they are often innocuous at the time of presentation, emphasizing the need for a multidisciplinary diagnostic approach using biochemical analysis, standard cross-sectional imaging, and newer advances in nuclear medicine. Similarly, treatment of both primary and disseminated carcinoid disease reflects the need for a multidisciplinary approach, with surgery remaining the only curative modality. The prognosis for patients with these tumors is generally favorable; however, it can be quite variable and is related to the location of the primary tumor, extent of metastatic disease at initial presentation, and time of diagnosis.

---

### Metastatic carcinoid tumors: a clinical review [^0f289ae2]. The Oncologist (2005). Low credibility.

Carcinoid tumors are neuroendocrine tumors derived from enterochromaffin cells, which are widely distributed in the body. They can originate from any location in the body, but they are traditionally described as originating from the foregut, midgut, and hindgut. Although the overall incidence of carcinoid tumors appears to have increased in the past decades, the prognosis for patients with metastatic carcinoid tumors has improved during the last decade. Due to longer survival times, complications, such as carcinoid heart disease, and new metastatic patterns, like skin and bone metastases, may become more important features of carcinoid disease. Therapy focused on these complications should be part of the management. Combining new diagnostic and treatment modalities in metastatic carcinoid patients may result in better quality of life and longer survival times. The increasing number of therapeutic options and diagnostic procedures requires a multidisciplinary approach, with decisions made in multidisciplinary meetings focused on "tailor-made" therapy based on patients' specific conditions. Because carcinoid tumors are uncommon, effort should be made to treat these patients in specialized centers and for these centers to join together in multicenter studies.

---

### A 50-year analysis of 562 gastric carcinoids: small tumor or larger problem? [^4a931a83]. The American Journal of Gastroenterology (2004). Low credibility.

Objectives

Interest in gastric carcinoid tumors has amplified considerably given the biological establishment of their relationship to gastrin and advances in the elucidation of the pathobiology of such lesions. The recognized propensity of acid-suppressing agents such as the proton pump inhibitor class of drugs to increase plasma gastrin levels has been proposed as a causal relationship in the apparent increase in the identification of such lesions although the increased prevalence of endoscopy and the enhanced awareness of pathologists have also been considered as contributory factors. We sought to examine if there has been an increase in gastric carcinoid incidence time correlative with these parameters.

Methods

Carcinoid tumor cases from the End Results Group (1950–1969) and the Third National Cancer Survey (TNCS) (1969–1971) databases were combined with the most recent release of the National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) registry (1973–1999); these three datasets revealed 13715 carcinoid cases, of which 562 were gastric in origin. Age-adjusted analyses as well as population-based gender and race correction ratios were completed in conjunction with United States decennial census data. To allow a finer granularity in incidence trends, the SEER database was divided into early (1973–1991) and late (1991–1999) subsets. RESULTS Since 1950, the percentage of gastric carcinoids among all gastric malignancies has increased from 0.3% to 1.77%. Since 1969, the proportion of gastric carcinoids among all enteric carcinoid lesions has increased from 2.4% to 8.7%. Age-adjusted incidence rates among male, female, black, and white population subsets have all increased since the TNCS time period, with the greatest increase (800%) noted in white females. The male:female ratio has fallen from 0.90 to 0.54. The occurrence of synchronous or metachronous noncarcinoid tumors with gastric carcinoid tumors has decreased by 26% during the course of SEER data collection. The 5-yr survival rate for gastric carcinoids overall has risen from 51% to 63% during the same time period.

Conclusions

Gastric carcinoids have increased in incidence over the last 50 yr. Differential increases in predominance across gender and race subdivisions may reflect genetic-based propensities (or protection) for gastric carcinoid tumors among certain ethnic populations. Increased endoscopic surveillance and associated sophisticated pathological evaluation of gastric biopsies undoubtedly are responsible for some of the observed increase in the incidence of gastric carcinoid tumors. These data allow no specific role to be assigned to the effects of acid-suppressive medications. Nevertheless the role of such agents cannot be discounted at this time since the time frame of the increased incidence is somewhat comparable to the introduction of these agents as is the known biological effect of gastrin on ECL cell proliferation.

---

### Development and validation of a simple-to-use nomogram to predict liver metastasis in patients with pancreatic neuroendocrine neoplasms: a large cohort study [^4aefde54]. BMC Gastroenterology (2021). Medium credibility.

Methods

Study population and data sources

The data were extracted from the Surveillance, Epidemiology, and End Results (SEER) database using SEER*Stat software Version 8.3.6. Data from patients with pNEN diagnosed in 2010–2016 who had complete information including age, sex, race, primary site, grade, marital status, T stage, N stage, tumor size, histology, and metastasis site, were included in the study. Pancreatic neuroendocrine neoplasms were selected on the basis of International Classification of Disease codes (ICD-O-3), including carcinoma (8150), malignant beta-cell tumor (8151), malignant alpha-cell tumor (8152), G-cell tumor (8153), VIPoma (8155), malignant somatostatinoma (8156), carcinoid tumor (8240), carcinoid tumor (8240) and atypical carcinoid tumor (8249). The exclusion criteria were as follows: (1) patients without definitive liver metastasis data; (2) patients with more than one primary cancer; and (3) patients without definitive grade and metastasis site information.

---

### One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35, 825 cases in the United States [^5ef6f294]. Journal of Clinical Oncology (2008). Low credibility.

PURPOSE Neuroendocrine tumors (NETs) are considered rare tumors and can produce a variety of hormones. In this study, we examined the epidemiology of and prognostic factors for NETs, because a thorough examination of neither had previously been performed. METHODS The Surveillance, Epidemiology, and End Results (SEER) Program registries were searched to identify NET cases from 1973 to 2004. Associated population data were used for incidence and prevalence analyses. Results We identified 35,618 patients with NETs. We observed a significant increase in the reported annual age-adjusted incidence of NETs from 1973 (1.09/100,000) to 2004 (5.25/100,000). Using the SEER 9 registry data, we estimated the 29-year limited-duration prevalence of NETs on January 1, 2004, to be 9,263. Also, the estimated 29-year limited-duration prevalence in the United States on that date was 103,312 cases (35/100,000). The most common primary tumor site varied by race, with the lung being the most common in white patients, and the rectum being the most common in Asian/Pacific Islander, American Indian/Alaskan Native, and African American patients. Additionally, survival duration varied by histologic grade. In multivariate analysis of patients with well-differentiated to moderately differentiated NETs, disease stage, primary tumor site, histologic grade, sex, race, age, and year of diagnosis were predictors of outcome (P < .001). CONCLUSION We observed increased reported incidence of NETs and increased survival durations over time, suggesting that NETs are more prevalent than previously reported. Clinicians need to be become familiar with the natural history and patterns of disease progression, which are characteristic of these tumors.

---

### Follow-up and surveillance of the patient with lung cancer after curative-intent therapy: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines [^689f5626]. Chest (2013). Medium credibility.

Follow-up and surveillance after curative-intent therapy — recommendations: In patients who have undergone curative-intent surgical resection of non-small cell lung cancer (NSCLC), it is suggested that chest CT be performed every 6 months for the first 2 years after resection and every year thereafter (Grade 2C). For patients with NSCLC or carcinoid tumor who have undergone curative-intent therapy, it is recommended that the original treating physicians participate in the decision-making process during the follow-up and surveillance (Grade 1C). After curative-intent therapy in patients with NSCLC or carcinoid tumors, routine surveillance with PET imaging, somatostatin receptor scintigraphy (SRS), or abdominal ultrasonography is not recommended (Grade 1C).

---

### Epidemiological classification changes and incidence of early-onset colorectal cancer [^483c9378]. JAMA Network Open (2025). High credibility.

All incident solid colorectal cancers diagnosed between 2004 and 2021 in inhabitants of 7 French administrative areas (Calvados, Côte-d'Or, Doubs, Finistère, Hérault, Isère, and Saône-et-Loire) were included in this cohort study. Rules of the International Agency for Research on Cancer allow for the inclusion of only 1 cancer per body site during a patient's lifetime, unless there are multiple cancers of different histological types. If there were multiple synchronous colorectal tumors in the same patient, the most advanced stage was included.

According to ICD-O-3, the cancer sites were the colon (ICD-O-3 code C18), including the appendix (ICD-O-3 code C18.1), rectosigmoid junction (ICD-O-3 code C19), and rectal ampulla (ICD-O-3 code C20). Adenocarcinoma (ADC) codes were 8140–8149, 8160–8163, 8190–8221, 8250–8384, 8390–8420, 8430, 8440–8490, 8500–8543, 8550–8552, and 8570–8576. Neuroendocrine neoplasms (NENs) included all neuroendocrine tumors, carcinomas, and mixed types; NEN codes were as follows: 8013, 8150–8158, and 8240–8249. Other rare histological types were included only when considering all colorectal cancer histological types (CRC-All). Stage at diagnosis for ADC was coded using the pathological TNM Classification of Malignant Tumours: stages I (T1-2, N0M0), II (T3-4, N0M0), III (all T, N1-2M0), and IV (M1). Additionally, unresected, nonmetastatic colorectal ADC was classified as the M0 unresected stage. For some analyses, stages I, II, III, and M0 unresected were grouped into ADC M0. For NENs, stage at diagnosis was defined as NEN M0 for no distant metastasis and NEN M1 for distant metastasis. Metastatic status was unknown for 1285 ADCs and 77 NENs; therefore, they were excluded from stage-specific analyses. Age at diagnosis was classified into 15 to 39 years, 40 to 49 years, and 50 years or older age classes. For the descriptive analysis of specific incidence rates, the 18-year time frame between 2004 and 2021 was divided into 6 periods of 3 years.

---

### Assessing cancer history accuracy in primary care electronic health records through cancer registry linkage [^c717105d]. Journal of the National Cancer Institute (2021). Medium credibility.

Identifying Cancer History in EHR Data

We identified EHR cancer history from ICD-9-CM and ICD-10-CM codes in problem list, medical history, and encounter diagnosis records. We limited our search to diagnosis codes indicating malignant cancers and benign brain or central nervous system tumors, excluding nonmelanoma skin cancers to align with cancer registry inclusion criteria. To standardize cancer site groupings, we mapped ICD-9-CM and ICD-10-CM codes to ICD-O-3 using National Cancer Institute's Surveillance, Epidemiology, and End Results Program documentation.

Determining Cancer History Overlap Between EHR and Registry Data

Cancer diagnoses were grouped into primary sites following classifications from the Surveillance, Epidemiology, and End Results Program. A small percentage of dates in each data source was missing month or day information; for these, we imputed mid-month or mid-year to construct a complete date, as is standard in cancer reporting.

Hereafter, we reference 3 units of analysis. Cancer patients are patients with any documented cancer history. Sites refer to individual cancer sites (eg, breast, colorectal); patients may have documentation of more than 1 site, and/or different sites recorded in the EHR and registry. Patient*site is the unique combination of a given cancer site for a given patient. Overall cancer status was ascertained from both EHR and registry data, with diagnosis date assigned as the earliest date of any cancer documented across the 2 data sources. For patient-level comparisons, patients were not required to have the same cancer site as cancer survivors to be considered in agreement. For patient*site comparisons, we required the same patient to have the same site documented in both the EHR and registry to be a match.

---

### Frequency of carcinoid syndrome at neuroendocrine tumour diagnosis: a population-based study [^e20c2c51]. The Lancet: Oncology (2017). Medium credibility.

Background

Neuroendocrine tumours (NETs) can secrete bioactive amines into the bloodstream, causing carcinoid syndrome, with symptoms including flushing and diarrhoea. However, carcinoid syndrome frequency in the NET population has never been rigorously assessed, nor has its relationship to presenting clinicopathological characteristics. This analysis assessed the proportion of patients with NETs and carcinoid syndrome in the USA and associated clinical factors.

Methods

We identified patients (≥ 65 years of age) from the Surveillance, Epidemiology, and End Results-Medicare database, excluding those with pancreatic tumours or small-cell or large-cell lung cancer, as well as those without complete data. We assessed the incidence of patients with at least two insurance claims of flushing, diarrhoea, or carcinoid syndrome during the 3 months before and after NET diagnosis. We compared demographic and clinical characteristics between patients with and without carcinoid syndrome using χ² tests. We used the Cochran-Armitage trend test to identify trends in carcinoid syndrome incidence and Cox regression to assess the relationship between carcinoid syndrome and survival.

Findings

Between April 1, 2000, and Dec 31, 2011, 9512 eligible patients were diagnosed with NETs, of whom 1786 (19%) had carcinoid syndrome. The number of patients with NETs and carcinoid syndrome increased from 50 (11%) of 465 patients in 2000 to 160 (19%) of 854 in 2011 (p < 0.0001). The proportion of patients with carcinoid syndrome compared with those without did not differ significantly with respect to age at diagnosis (p = 0.65), geographical region (p = 0.054), or urban versus rural status (p = 0.53). Patients with carcinoid syndrome were more frequently female than male (p = 0.0003). Race was associated with a significant difference in the reported incidence of carcinoid syndrome (p < 0.0001), as was tumour grade, stage, and primary tumour site (all p < 0.0001). Patients with carcinoid syndrome had a shorter overall survival (median 5 years [95% CI 4.5–5.4]) than did those without carcinoid syndrome (5.6 years [5.4–5.9]; hazard ratio 1.102 [1.016–1.194]; p = 0.019). Use of octreotide (p < 0.0001) and chemotherapy (p = 0.003) were more common in patients with carcinoid syndrome than in those without it, whereas surgery was used more frequently in patients without carcinoid syndrome (p = 0.009); use of radiotherapy was not significantly associated with the presence of carcinoid syndrome at diagnosis (p = 0.07).

Interpretation

This population-based analysis reveals that carcinoid syndrome is significantly associated with tumour grade, stage, and primary tumour site, and leads to shorter survival compared with those patients without carcinoid syndrome. An improved understanding of the heterogeneity of presenting symptoms among patients with NETs might permit more tailored assessment and management than at present and enable future research into the effect of carcinoid syndrome control on patient survival.

Funding

Ipsen.

---

### Epidemiology and classification of gastroenteropancreatic neuroendocrine neoplasms using current coding criteria [^b2d96813]. The British Journal of Surgery (2016). Low credibility.

Abstract

Background

The lack of uniform criteria for coding of gastroenteropancreatic neuroendocrine neoplasia has hampered previous epidemiological studies. The epidemiology ofwas investigated in this study using currently available criteria.

Methods

All patients diagnosed withbetween January 2003 and December 2013 in a well defined Norwegian population of approximately 350 000 people were included. Age‐ and sex‐adjusted incidence rates were calculated. The current 2010 World Health Organization criteria, European Neuroendocrine Tumour Society classification and International Union Against Cancer classification were used.

Results

A total of 204 patients (114 male, 55.9 per cent) were identified. The median age at diagnosis was 61 (range 10–94) years. The annual overall crude incidence was 5.83 per 100 000 inhabitants, with an increasing trend (0.033). The most frequent location was small intestine (60 patients, 29.4 per cent) followed by appendix (48 patients, 23.5 per cent) and pancreas (33 patients, 16.2 per cent). Grade 1 tumours were more common in gastrointestinal (100 patients, 58.5 per cent) than in pancreatic (9 patients, 27 per cent). According to theclassification, 77 patients (37.7 per cent) had stage I, 17 patients (8.3 per cent) stage, 37 patients (18.1 per cent) stageand 70 patients (34.3 per cent) had stagedisease. No patient with stage I disease had grade 3 tumours; advanced tumour grade increased with stage.

Conclusion

A high crude incidence of, at 5.83 per 100 000 inhabitants, was noted together with a significant increasing trend over time.

---

### Occult primary, version 3.2014 [^72040312]. Journal of the National Comprehensive Cancer Network (2014). Medium credibility.

Occult primary — recommendation category: All recommendations are category 2A unless otherwise indicated.

---

### The surgical management of small bowel neuroendocrine tumors: consensus guidelines of the North American Neuroendocrine Tumor Society [^48f997c6]. Pancreas (2017). Medium credibility.

Regarding specific circumstances for small bowel neuroendocrine tumors, more specifically with respect to patients with liver metastases and unknown primaries, NANETS 2017 guidelines recommend to obtain thin-slice multiphase CT of the abdomen, pelvis, and chest to evaluate the bronchi, thymus, stomach, duodenum, colorectum, appendix, pancreas, and small bowel with its mesentery for the staging of patients with NET liver metastases and unknown primaries.

---

### Update on incidence, prevalence, treatment and survival of patients with small bowel neuroendocrine neoplasms in the Netherlands [^b9da82cb]. World Journal of Surgery (2021). Medium credibility.

Data collection

Primary tumour location was classified as jejunum (C17.1), ileum (C17.2) or small bowel not otherwise specified (C17.9), according to the ICD-O-3 codes. C17.9 reports were checked manually for tumour location. Tumour grade was based on the Ki67 index or mitoses index reported in the pathology reports, whichever was higher. Tumour stage was reported based on the pathological tumour-node-metastasis (TNM) classification at the time of registration (6th edition during 2003–2009 and 7th edition during 2010–2016), supplemented with the clinical TNM classification. A one-digit summary stage (Extent of Disease) was recorded in patients without pathological confirmation of cancer. The Extent of Disease code is used for patients who had no TNM stage available.

Data in both NCR and PALGA databases correspond based on unique NCR-codes. This feature was used to couple both datasets. Data regarding topography (site of primary), differentiation grade, resection margins, TNM staging, tumour positive lymph nodes reported by the NCR were cross-checked with the full pathology reports provided by PALGA. Morphology codes (cell of origin) were used in case of a mismatch in differentiation grade. Data from PALGA prevailed, in case of disagreement between both datasets, because the pathology reports are more detailed. Tumour grading was based on the WHO 2010 classification. Finally, all tumours were restaged according to the 8th edition of the TNM classification to avoid differences between different TNM classifications. The study period was divided into three time periods (2005–2007, 2008–2011 and 2012–2015), based on the publication date of the ENETS guidelines to compare different treatment strategies, stratified for disease stage. NCR only includes treatments 9 months before or after diagnosis.

In case of multiple pathology reports (e.g. one biopsy followed by resection), the first date was used for survival analyses. Time to treatment analyses could not be performed because the diagnosis was based on pathology data, which was often the date of surgery. Survival was defined as the time between date of diagnosis and date of death or censored at last follow-up date. Records of patients with pathologically proven recurrences were assessed for possible tumour dedifferentiation (i.e. tumour grade change from G1 to G2). Incidental diagnosis was defined as a patient whose first pathology report describes a resection with signs of ileus/stenosis/perforation, without previous biopsy available.

---

### Neuroendocrine and adrenal tumors, version 2.2021, NCCN clinical practice guidelines in oncology [^d9fecc53]. Journal of the National Comprehensive Cancer Network (2021). High credibility.

Carcinoid syndrome — continuation of somatostatin analogs on progression: If clinically significant disease progression, treatment with octreotide LAR or lanreotide should be discontinued for non-functional tumors and continued in patients with functional tumors; these regimens may be used in combination with any of the subsequent options.

---

### Symptom management for well-differentiated gastroenteropancreatic neuroendocrine tumors: ASCO guideline [^da56de01]. JCO Oncology Practice (2025). High credibility.

Cost implications for neuroendocrine tumor (NET) care — Increasingly, individuals with cancer are required to pay a larger proportion of their treatment costs through deductibles and coinsurance, and higher patient out-of-pocket costs have been shown to be a barrier to initiating and adhering to recommended cancer treatments.

---

### Diagnostic category prevalence in 3 classification systems across the transition to the international classification of diseases, tenth revision, clinical modification [^b7ad7b35]. JAMA Network Open (2020). High credibility.

Key Points

Question

Was the transition from International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) to the Tenth Revision (ICD-10-CM) in October 2015 associated with changes in diagnostic category prevalence when diagnoses are grouped by classification system?

Findings

This interrupted time series analysis and cross-sectional study examined insurance claims for more than 18 million privately insured adults and children in the US from 2010 to 2017 and found instantaneous increases or decreases of 20% or more associated with the ICD-10-CM transition for nearly 1 in 6 (16%) diagnostic categories in 2 of 3 influential diagnostic classification systems.

Meaning

These findings suggest that diagnostic classification systems developed with ICD-9-CM data may need to be refined for use with ICD-10-CM data for disease surveillance, performance assessment, or risk-adjusted payment.

---

### Neuroendocrine neoplasms of the lung [^f80a5f56]. American Journal of Clinical Pathology (2001). Low credibility.

Neuroendocrine tumors of the lung continue to be difficult nosologic and diagnostic problems, centering on the time-honored terms of "carcinoid", "atypical carcinoid", and "small cell carcinoma". Problems that are encountered in the classification of such neoplasms revolve around the differing criteria that have been advanced for their definition and variable application of such criteria in common practice. This review considers the epithelial and nonepithelial lesions of the lung that may demonstrate neuroendocrine and neuroectodermal differentiation. A proposal is made for a simplified system of classifying the epithelial tumors, dividing them into 3 grades with appended descriptive modifiers.

---

### Neuroendocrine and adrenal tumors, version 2.2021, NCCN clinical practice guidelines in oncology [^bee5031c]. Journal of the National Comprehensive Cancer Network (2021). High credibility.

Evaluation of locoregional advanced disease and/or distant metastatic gastrointestinal tract, lung, and thymic neuroendocrine tumors — imaging recommendations include multiphase technique computed tomography (CT) or magnetic resonance imaging (MRI) at baseline and to assess disease progression; the most common sites of metastases from intestinal NETs include regional/mesenteric lymph nodes, liver, and bones; when evaluating locoregional advanced and/or metastatic NETs of the GI tract, lung, and thymus, or for suspected carcinoid syndrome, multiphasic abdomen/pelvis CT or MRI scans with IV contrast are recommended; chest CT scans with or without contrast are recommended as clinically indicated, with non-contrast acceptable when evaluating for metastases from primary tumors in other sites.

---

### Neuroendocrine and adrenal tumors, version 2.2021, NCCN clinical practice guidelines in oncology [^b7341e61]. Journal of the National Comprehensive Cancer Network (2021). High credibility.

Special-category notes for grading: PDNECs are not formally graded but are considered high grade by definition, and for MiNENs the neuroendocrine and non-neuroendocrine components are often poorly differentiated with proliferation indexes in the same range as other NECs; this category allows that one or both components may be well differentiated, and when feasible each component should therefore be graded separately.

---

### Pediatric application of coding and valuation systems [^d495525c]. Pediatrics (2019). High credibility.

ICD-10-CM impact on payment — Pediatricians "should use the specificity of the ICD-10-CM to accurately reflect the child's conditions and complexity", and when "sufficient clinical information is not known or available about a particular health condition, the payer should recognize that the clinician can appropriately report an unspecified code without the claim being summarily denied solely on the basis of specificity". Furthermore, payers "should not use ICD-10-CM specificity to deny payment to appropriately trained pediatricians performing those specialized services within their scope of practice". New payment models "incorporate elaborate risk-adjustment algorithms based on diagnostic completeness", and such risk-based models "must appropriately represent the risk contributed by children with special health care needs". To support diagnostic comprehensiveness, "claim-form formatting should be expanded (such as doubling to 8) to accommodate more than 4 diagnoses per line-item service", exceeding "the current line-item limitation for the version 5010 CMS 837P electronic and 1500 paper claim forms".

---

### Neuroendocrine and adrenal tumors, version 2.2021, NCCN clinical practice guidelines in oncology [^fe3d200d]. Journal of the National Comprehensive Cancer Network (2021). High credibility.

Carcinoid syndrome — cardiac evaluation and disease surveillance — should include periodic echocardiography and cross-sectional imaging. An echocardiogram should be performed every 1 to 3 years or as clinically indicated for patients without carcinoid heart disease (CHD), and at least annually for those with established CHD; CHD is frequent, with one study reporting 59% of patients with carcinoid syndrome diagnosed with tricuspid regurgitation. A study of 250 patients showed that 5-HIAA levels of ≥ 300 μmol (57 mg) over 24 hours and ≥ 3 flushing episodes per day were associated with higher CHD risk. To monitor disease control and/or progression, multiphasic abdomen/pelvis CT or MRI every 12 weeks to 12 months and chest CT scans (with or without contrast) should be performed as clinically indicated.

---

### Priorities for improving the management of gastroenteropancreatic neuroendocrine tumors [^79d3896c]. Journal of the National Cancer Institute (2008). Low credibility.

A National Cancer Institute summit meeting on gastroenteropancreatic neuroendocrine and carcinoid tumors was held in September 2007 to present the currently accepted standards of care for patients with these tumors and to identify areas requiring investigation and development. These tumors are clinically and pathologically heterogeneous, present commonly with obscure symptoms that lead to delays in diagnosis of years, and have an incidence in the United States of 2.5 to 5 cases per 100,000. The 5-year survival rates range between 15% and 95%, depending on the site and extent of disease. This report delineates the main conclusions of the meeting, including the best practice diagnosis and treatment strategies for gastropancreatic neuroendocrine tumors, and the identification of clinical and scientific areas that are most in need of attention. The most pressing needs were public and physician education, identification of molecular markers for early diagnosis and therapeutic monitoring, improved imaging modalities and molecular prognostication, development of a standardized pathological classification system, and creation of regional centers of expertise with tumor and laboratory data banks. In addition, adequately validated neuroendocrine tumor models and cell lines should be established to investigate the molecular mechanisms involved in the control of their growth and secretion, and to facilitate the development of specific therapies that should be examined in well-designed multicenter studies of defined patient groups.

---

### Neuroendocrine and adrenal tumors, version 2.2021, NCCN clinical practice guidelines in oncology [^adc29933]. Journal of the National Comprehensive Cancer Network (2021). High credibility.

NET-6 molecular profiling — pathology guidance adds Consider molecular profiling of tumor tissue (for atypical carcinoid), and footnote y states that tumor/somatic molecular profiling should be considered for patients with locoregional unresectable/metastatic disease who are candidates for anticancer therapy to identify actionable alterations; testing on tumor tissue is preferred, and liquid biopsy can be considered if tumor tissue testing is not feasible.

---

### Epidemiology and classification of gastroenteropancreatic neuroendocrine neoplasms using current coding criteria [^1b397096]. The British Journal of Surgery (2016). Low credibility.

Figure 2
World Health Organization tumour grade by organ. Of note is the wide variation in tumour grade between locations; low‐grade tumours are most commonly encountered in the duodenum, small intestine and appendix

Half of patients (98, 48.0 per cent) had regional lymph node metastases, and more than one‐third (70, 34.3 per cent) had distant organ metastases (liver, lung and distant lymph nodes) at the time of diagnosis. Ten of 15 patients with colonic NEN presented with distant organ metastases, whereas only one of the 48 patients with a primary appendiceal NEN had distant metastases. Regional lymph node involvement was present in most patients with NEN in the small intestine (52 of 60) and colon (12 of 15).

According to the UICC classification, 77 patients (37.7 per cent) had stage I, 17 patients (8.3 per cent) stage II, 37 patients (18.1 per cent) stage III and 70 patients (34.3 per cent) had stage IV disease. No patient with stage I disease had grade 3 tumours; advanced tumour grade increased with stage. The distribution of tumour location by stage according to the UICC classification and ENETS criteria is presented in 3. There was notable discordance with respect to these staging systems for appendiceal and pancreatic neoplasms.

Figure 3
Distribution by tumour location according to stage at the time of diagnosis. *European Neuroendocrine Tumour Society (ENETS) criteria (based on 200 patients; lack of information for staging in 4 patients). †International Union Against Cancer (UICC) criteria (based on 201 patients; lack of information for staging in 3 patients). Where the ENETS and UICC criteria are similar for a given location, a single column is presented. Otherwise, data for the two classification systems are shown separately

---

### Atypical presentation of an atypical carcinoid [^c35eafef]. The Annals of Thoracic Surgery (2009). Low credibility.

Carcinoids are malignant neuroendocrine tumors consisting of a spectrum of neoplasms from low-grade typical carcinoid to high-grade small cell carcinoma. Primary neuroendocrine lesions in the mediastinum, especially the thymic region, are rare. Therefore, presently no uniform criteria are available for diagnosis, staging, risk assessment, and treatment. Generally, carcinoid tumors are indolent. However, when they occur in the thymic region, these tumors should be considered as aggressive neoplasms with an elevated risk of local recurrence and distant metastases.

---

### The impact of conversion to international classification of diseases, 10th revision (ICD-10) on an academic ophthalmology practice [^a400e9f3]. Clinical Ophthalmology (2018). Low credibility.

There was no overall difference in coder efficiency in the 1-year periods before and after ICD-10 implementation (P = 0.76). However, we noted a reduction in coder efficiency during the first 4 months (October 2015 to January 2016) after ICD-10 conversion, which returned to baseline for the remaining 8 months (Figure 2).

---

### A national study of surgically managed atypical pulmonary carcinoid tumors [^f3fd75c4]. The Annals of Thoracic Surgery (2021). Medium credibility.

Background

Atypical pulmonary carcinoid tumors represent a subset of non-small cell lung cancer; however, their relative infrequency has left prognosis, management and long-term survival associated with atypical carcinoids, incompletely characterized.

Methods

Patients aged 18 years or more diagnosed with atypical or typical pulmonary carcinoid between 2010 and 2015 within the National Cancer Database were evaluated. Survival was measured using Kaplan-Meier survival and multivariable Cox proportional hazards regression, adjusting for patient and tumor attributes.

Results

A total of 816 atypical and 5688 typical carcinoid patients were identified in the cohort. Patients with atypical carcinoids tended to be older, have larger tumors, and later stage disease. The unadjusted overall 5-year survival for atypical carcinoid patients was 84%, 74%, 52%, and 51% for stages I, II, III, and IV, respectively. The unadjusted 5-year survival for typical carcinoids was 93%, 93%, 89%, and 87% for stages I, II, III, and IV, respectively. Nodal upstaging (ie, lymph node metastases identified in surgical specimens of clinically staged N0 patients) was seen in 16% of atypical and 7% of typical carcinoid patients. Increasing age, comorbidities, and stage were identified as significant predictors of mortality for atypical patients in multivariable analysis. Extent of surgical resection (lobectomy vs sublobar) was not identified as a predictor of survival for atypical carcinoid.

Conclusions

Atypical carcinoid tumors represent a distinct subset of carcinoid tumors, with a tendency toward more aggressive behavior. Further study of the optimal surgical management is warranted.

---

### Contributions of adenocarcinoma and carcinoid tumors to early-onset colorectal cancer incidence rates in the United States [^ef419bb7]. Annals of Internal Medicine (2021). Medium credibility.

Background

Early-onset colorectal cancer (EOCRC) incidence rates (IRs) are rising, according to previous cancer registry analyses. However, analysis of histologic subtypes, including adenocarcinoma (the focus of CRC screening and diagnostic testing) and carcinoid tumors (which are classified as "colorectal cancer" in SEER [Surveillance, Epidemiology, and End Results] databases but have a distinct pathogenesis and are managed differently from adenocarcinoma), has not been reported.

Objective

To assess EOCRC IRs and changes in IRs over time, stratified by histology.

Design

Retrospective analysis.

Setting

Yearly IRs according to SEER 18 data from 2000 to 2016 on age-specific colon-only, rectal-only, and combined-site CRC cases, stratified by histology ("overall" CRC [all histologic subtypes], adenocarcinoma, and carcinoid tumors) and age.

Patients

119624 patients with CRC.

Measurements

IRs per 100000 population, changes in 3-year average annual IRs (pooled IRs from 2000 to 2002 vs. those from 2014 to 2016), and annual percentage change (APC) in persons aged 20 to 29, 30 to 39, 40 to 49, and 50 to 54 years.

Results

The steepest changes in adenocarcinoma 3-year average annual IRs were for rectal-only cases in persons aged 20 to 29 years (+39% [0.33 to 0.46 per 100000]; P < 0.050) and 30 to 39 years (+39% [1.92 to 2.66 per 100000]; P < 0.050) and colon-only cases in those aged 30 to 39 years (+20% [3.30 to 3.97 per 100000]; P < 0.050). Corresponding APCs were 1.6% (P < 0.050), 2.2% (P < 0.050), and 1.2% (P < 0.050), respectively. In persons aged 40 to 49 years, 3-year average annual IRs increased in both colon-only (+13% [12.21 to 13.85 per 100000]; P < 0.050) and rectal-only (+16% [7.50 to 8.72 per 100000]; P < 0.050) subsites. Carcinoid tumors were common, representing approximately 4% to 20% of all colorectal and 8% to 34% of all rectal cancer cases, depending on age group and calendar year. Colon-only carcinoid tumors were rare. Colorectal carcinoid tumor IRs increased more steeply than adenocarcinoma in all age groups, thus affecting the contribution of carcinoid tumors to overall cancer cases over time. These changes were driven by rectal subsites and were most pronounced in persons aged 50 to 54 years, in whom rectal carcinoid tumors increased by 159% (2.36 to 6.10 per 100000) between 2000 to 2002 and 2014 to 2016, compared with 10% for adenocarcinoma (18.07 to 19.84 per 100000), ultimately accounting for 22.6% of all rectal cancer cases.

Limitation

Population-based data.

Conclusion

These findings underscore the importance of assessing histologic CRC subtypes independently. Doing so may lead to a better understanding of the drivers of temporal changes in overall CRC incidence and a more accurate measurement of outcomes from efforts to reduce adenocarcinoma risk, and can guide future research.

Primary Funding Source

None.

---

### Neuroendocrine and adrenal tumors, version 2.2021, NCCN clinical practice guidelines in oncology [^5cb0f057]. Journal of the National Comprehensive Cancer Network (2021). High credibility.

Staging tables — staging table for Lung was updated to Version 9, 2024, and staging table for Thymus was updated to Version 9, 2024.

---

### Epidemiology of gastrointestinal neuroendocrine tumors in a U.S. commercially insured population [^6fe84a0b]. Endocrine Practice (2017). Low credibility.

Objective

To estimate incidence and prevalence of gastrointestinal neuroendocrine tumors (GI NETs) in U.S. commercially insured patients.

Methods

This was a retrospective, cross-sectional study using 2009 to 2014 data from MarketScan and PharMetrics commercial claims databases. Patients were 18 to 64 years old, and had 1 inpatient or 2 outpatient claims with GI NET, identified by International Classification of Diseases, 9th Revision, Clinical Modification codes. Incidence was calculated as number of patients with NET who were disease-free for 2 years prior, divided by number of enrollees and reported as per million person-years (PMPY). Prevalence was calculated as the number of GI NET patients divided by the number of enrollees per year.

Results

The annual number of patients with GI NET ranged from 2,014 to 3,413 in MarketScan and 1,436 to 2,336 in PharMetrics. Incidence increased from 2011 to 2014: 67.0 to 79.1 PMPY in MarketScan and 47.4 to 58.2 PMPY in PharMetrics. Incidence increased by 24.3% in females and 10.7% in males in MarketScan, and by 17.6% in females and 29.3% in males in PharMetrics. Incidence increased with age and was highest in the 45 to 54 and 55 to 64 age groups. Prevalence increased from 77.9 to 131.2 per million per year (MarketScan) and 50.8 to 108.9 (PharMetrics) from 2009 to 2014. Prevalence was generally higher in females than males and highest in 55 to 64 year olds. These increases may be due to better diagnostics, increased awareness of NET among clinicians and pathologists, and/or actual increase in disease.

Conclusion

Clinicians may see GI NET with increasing frequency and should become more familiar with its presentation and treatment.

Abbreviations

GI = gastrointestinal; ICD-9-CM = International Classification of Diseases, 9th Revision, Clinical Modification; NET = neuroendocrine tumor; PMPY = per million person-years; SEER = Surveillance, Epidemiology, and End Results.

---

### Second primary malignancies in patients with male breast cancer [^96faaa06]. British Journal of Cancer (2005). Low credibility.

RESULTS

The numbers of men diagnosed with a first primary breast cancer are shown in Table 1 by various characteristics. A total of 3409 men was diagnosed, and of these 426 (12.5%) subsequently developed a second primary neoplasm. More than half of all men were over 65 years at diagnosis, as many as 25% were diagnosed before year 1975, and the most common follow-up period was 1–4 years (41.1% of all men).

The SIRs for second neoplasms by length of follow-up are shown in Table 2 for sites for which at least four cases were recorded in the overall analysis. In the overall analysis, all malignancies were increased by 34%. The highest SIRs were found for small intestine (4.95) and myeloid leukaemia (3.42); among small intestinal tumours, two were carcinoids, one was carcinoma and another one was histologically unspecified. Other specific sites of increased SIRs were the rectum (1.78), pancreas (1.93), (nonmelanoma) skin (1.65) and prostate (1.61). Nonmelanoma skin tumours were in excess only in the short follow-up period, < 12 months after breast cancer; liver cancer and leukaemias were increased only in the middle follow-up period (1–9 years); pancreatic cancer was only increased in the longest follow-up period (10+ years). Only prostate cancer was increased in two follow-up periods.